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Introduction {#sec007}
============

Epidemiological studies have demonstrated that maternal physical and physiological traits associate with birth outcomes. For example, maternal height is positively associated with gestational duration \[[@pmed.1003305.ref001], [@pmed.1003305.ref002]\], birth weight, and birth length \[[@pmed.1003305.ref003], [@pmed.1003305.ref004]\]; higher maternal blood glucose is associated with higher birth weight \[[@pmed.1003305.ref005]\]; and elevated maternal blood pressure (BP) is associated with reduced birth weight \[[@pmed.1003305.ref006], [@pmed.1003305.ref007]\]. These birth outcomes in turn associate with many long-term adverse health outcomes in the offspring, such as obesity \[[@pmed.1003305.ref008]\], type 2 diabetes (T2D) \[[@pmed.1003305.ref009]\], hypertension \[[@pmed.1003305.ref010]\], and cardiovascular diseases \[[@pmed.1003305.ref011], [@pmed.1003305.ref012]\]. Different mechanisms have been proposed to explain the observed associations between maternal phenotypes and pregnancy outcomes \[[@pmed.1003305.ref013]--[@pmed.1003305.ref016]\] ([Fig 1A](#pmed.1003305.g001){ref-type="fig"}), as well as the life-course associations between birth outcomes and adult phenotypes \[[@pmed.1003305.ref017]--[@pmed.1003305.ref020]\] ([Fig 1B](#pmed.1003305.g001){ref-type="fig"}). Briefly, these include various causal effects (for example, maternal effects, defined as the causal influence of the maternal phenotype on birth outcomes or offspring phenotype \[[@pmed.1003305.ref021]\]), genetically confounded associations due to genetic sharing (between mothers and infants) or shared genetic effects (between a birth outcome and an adult phenotype) \[[@pmed.1003305.ref020]\], and confounding due to the environment. Fetal phenotypes can also affect maternal physiology during or even after pregnancy (fetal drive) \[[@pmed.1003305.ref022]\]. Dissecting these different underlying mechanisms would increase knowledge of the etiology of these critical pregnancy outcomes and provide insights into how pregnancy outcomes are linked with later-onset disorders \[[@pmed.1003305.ref013], [@pmed.1003305.ref023]\]. Understanding the causal effects of modifiable maternal phenotypes could have implications for clinical interventions to prevent adverse birth outcomes \[[@pmed.1003305.ref024]\]. The shared genetic causes between pregnancy characteristics and late offspring outcomes could provide insights into the molecular pathways through which these shared genetic effects are mediated \[[@pmed.1003305.ref020]\].

![**The different mechanisms underlying (A) the associations between maternal phenotypes and pregnancy outcomes and (B) the associations between pregnancy outcomes and late adult phenotypes in offspring.** These mechanisms include 1) causal effects of maternal phenotypes on pregnancy outcomes ($\beta_{XY}^{m}$) and causal effects of pregnancy outcomes on adult phenotypes ($\beta_{YX^{\prime}}^{f}$) (green arrows), 2) genetically confounded associations between maternal phenotypes and pregnancy outcomes ($\beta_{XY}^{c}$) because of genetic sharing between mothers and infants and genetically confounded associations between birth outcomes and adult phenotypes in offspring ($\beta_{YX^{\prime}}^{c}$) because of shared genetic effects (blue dashed arrows), 3) confounding due to environmental effects (gray dashed arrows, which were not examined in this study), and 4) fetal drive ($\beta_{YX}^{f}$)---fetus causally influencing maternal phenotypes during pregnancy (red arrow).](pmed.1003305.g001){#pmed.1003305.g001}

Mendelian randomization (MR) \[[@pmed.1003305.ref025]\] studies utilizing maternal genotypes as instrumental variables have been used to probe the causal relationships between maternal phenotypes and pregnancy outcomes \[[@pmed.1003305.ref013], [@pmed.1003305.ref016], [@pmed.1003305.ref026]\]. Using this approach, Tyrrell and colleagues \[[@pmed.1003305.ref024]\] demonstrated that higher maternal body mass index (BMI) and blood glucose levels are causally associated with higher birth weight, whereas higher maternal systolic BP (SBP) causes lower birth weight. Using a genome-wide association (GWA) approach, Horikoshi and colleagues \[[@pmed.1003305.ref020]\] demonstrated strong inverse genetic correlations between birth weight and adult cardiometabolic diseases, suggesting a strong genetic component underlying the observed associations between low birth weight and cardiometabolic risks. More recently, Warrington and colleagues estimated maternal and fetal genetic effects on birth weight genome-wide and investigated associations between those genetic effects on birth weight and adult SBP \[[@pmed.1003305.ref027]\].

We previously developed an MR method that utilizes nontransmitted maternal alleles as a valid genetic instrument for maternal phenotypic effects on fetal/offspring outcomes \[[@pmed.1003305.ref015]\]. We showed that the observed association between maternal height and fetal size is mainly due to shared genetics, whereas the association between maternal height and gestational duration is more likely causal. Studies based on this approach have provided novel understandings about the causal relationships between many maternal phenotypes and birth outcomes. They have also highlighted genetic contributions to life-course associations between birth weight and late-onset diseases \[[@pmed.1003305.ref020], [@pmed.1003305.ref027]\]. However, previous studies have usually examined causal effects of maternal phenotypes on either birth weight or gestational duration separately despite the strong association between them \[[@pmed.1003305.ref028], [@pmed.1003305.ref029]\]. The studies focusing on birth weight have not explored whether any effects on birth weight are driven by effects on gestational duration because the information was not always available. In addition, the causal effects of fetal growth on gestational duration and maternal phenotypes during pregnancy have not been previously investigated using genetic approaches.

To further our understanding of how various maternal phenotypes are correlated with pregnancy outcomes through maternal or fetal genetic effects and how fetal growth influences gestational duration and maternal physiological changes during pregnancy, we expanded our haplotype-based method by considering the mother--fetus duo (pregnancy) as the analytical unit \[[@pmed.1003305.ref030]\] and explicitly modeled maternal and fetal genetic effects using haplotype genetic scores ([Fig 2](#pmed.1003305.g002){ref-type="fig"}). By testing associations between these haplotype genetic scores and birth outcomes, we systematically investigated the maternal and fetal genetic effects underlying the observed associations between 4 maternal traits (height, BMI, BP, and blood glucose levels) and pregnancy outcomes (gestational duration, birth weight, and birth length). Using this approach, we also examined the associations between fetal growth (using gestational-age--adjusted birth weight as a measure of this) and pregnancy outcomes, maternal BP, and maternal blood glucose levels measured during pregnancy.

![Genetic dissection of maternal and fetal genetic effects using haplotype genetic scores in mother--child pairs.\
There are 3 groups of alleles (haplotypes) in a mother (M)--fetus (F) duo: the maternal transmitted alleles (h1) can affect a pregnancy outcome through a maternal (1) and/or fetal genetic effect (2), the maternal nontransmitted alleles (h2) can only affect a pregnancy outcome through maternal effect (1), and the paternal transmitted alleles (h3) only through fetal effect (2) (assuming no paternal effect). The paternal transmitted alleles (h3) could influence a maternal phenotype during pregnancy by fetal drive (3). The paternal genetics might be able to influence maternal phenotype and pregnancy outcomes through the environment that the fathers create (i.e., paternal effect or "genetic nurture"). However, for the traits and their associated variants considered in this study ([S2 Table](#pmed.1003305.s005){ref-type="supplementary-material"}), the paternal effects should be minimal and therefore were assumed to be zero.](pmed.1003305.g002){#pmed.1003305.g002}

Methods {#sec008}
=======

A prospective protocol for analysis was not prepared for this study; however, the assembly of the data sets and all the analyses were planned in advance of data analysis. We reported this study according to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guideline \[[@pmed.1003305.ref031]\] for cross-sectional studies ([S1 STROBE Checklist](#pmed.1003305.s001){ref-type="supplementary-material"}). All data derived from the present study are presented with or in the paper.

Data sets {#sec009}
---------

We used phenotype and genome-wide single-nucleotide polymorphism (SNP) data of 10,734 mother--infant pairs from 6 birth studies ([S1 Table](#pmed.1003305.s004){ref-type="supplementary-material"}). These include 3 case/control data sets collected from Nordic countries (The Finnish birth data set \[FIN\], The Mother Child data set of Norway \[MoBa\], and The Danish National Birth Cohort \[DNBC\]) for genetic studies of preterm birth \[[@pmed.1003305.ref032]\], a longitudinal birth cohort (the Avon Longitudinal Study of Parents and Children \[ALSPAC\]) \[[@pmed.1003305.ref033]\] from the UK, a study of preterm birth from the US (The Genomic and Proteomic Network for Preterm Birth Research \[GPN\]) \[[@pmed.1003305.ref034]\], and the Hyperglycemia and Adverse Pregnancy Outcome \[HAPO\] study \[[@pmed.1003305.ref005]\] with samples of European ancestry collected from the UK, Canada, and Australia. A detailed description of these data sets can be found in the Supplementary Methods ([S1 Text](#pmed.1003305.s002){ref-type="supplementary-material"}).

We focused on investigating the relationships between maternal height, prepregnancy BMI, BP, blood glucose levels, and pregnancy outcomes including gestational duration (as both quantitative and dichotomous preterm/term trait), birth weight, and birth length. Maternal height, prepregnancy BMI, and the 3 pregnancy outcomes were available in most of the studies (birth weight and length were not available in the MoBa data used here, and birth length was not available in the DNBC data used here) ([Table 1](#pmed.1003305.t001){ref-type="table"}). Maternal BP during pregnancy was available in ALSPAC and HAPO. In the HAPO data, BP was measured between 24 and 32 weeks of pregnancy when the mothers underwent an oral glucose tolerance test (OGTT) \[[@pmed.1003305.ref005]\]. In ALSPAC, all BP measurements undertaken during antenatal care were extracted from clinical records; women had a median of 13 (interquartile range 11--16) BP measurements \[[@pmed.1003305.ref035]\]. We used the average of the BPs measured between 30 to 36 weeks of gestation (as close as possible to when the BP was measured in HAPO). Maternal fasting plasma glucose (FPG) levels during pregnancy were available only in the HAPO study. FPG was measured in over 4,000 ALSPAC mothers in a follow-up data collection 18 years after the pregnancy ([S1 Text](#pmed.1003305.s002){ref-type="supplementary-material"} and [Table 1](#pmed.1003305.t001){ref-type="table"}).

10.1371/journal.pmed.1003305.t001

###### Descriptive statistics of maternal traits and birth outcomes.

![](pmed.1003305.t001){#pmed.1003305.t001g}

  Trait                                                        FIN       MoBa      DNBC      HAPO      GPN       ALSPAC        Total                                                                                                                                
  ------------------------------------------------------------ --------- --------- --------- --------- --------- ------------- ------------- --------- --------- ------- --------- --------- ------- --------- --------- ------- ------- --------- -------- ------- -----
  ***Maternal traits***                                                                                                                                                                                                                                             
  Height (cm)                                                  1,170     166.7     5.8       975       167.9     5.8           1,653         168.9     6.1       1,089   164.5     6.2       342     164.9     7.8       4,993   164.4   6.6       10,222   165.7   6.4
  BMI (kg/m^2^)                                                1,168     23.0      3.7       958       24.0      4.2           1,625         23.5      4.2       1,051   24.2      4.7       337     24.2      5.3       4,759   22.9    3.7       9,898    23.3    4.0
  SBP (mmHg)                                                   NA        NA        NA        1,089     108.0     9.7           NA            4,923     113.1     6.8     6,012     112.1     7.4                                                                    
  DBP (mmHg)                                                   1,089     71.1      7.8       4,943     66.8      4.7           6,032         67.6      5.4                                                                                                          
  FPG (mmol/L)[^a^](#t001fn001){ref-type="table-fn"}           1,088     4.5       0.4       2,452     5.2       0.4           3,540         5.0       0.4                                                                                                          
  ***Birth outcomes***[^b^](#t002fn001){ref-type="table-fn"}                                                                                                                                                                                                        
  Gestational days                                             892       282.0     6.3       522       280.4     3.6           977           282.6     3.0       1,034   281.2     7.2       197     276.4     4.2       4,967   279.8   7.9       8,589    280.5   7.0
  255                                                          237.9     13.4      487       248.2     11.4      748           240.1         15.2      None      146     212.0     20.3      212     242.7     13.5      1,848   240.0   14.3                       
  Birth weight (g)                                             892       3,578.0   434.3     NA        973       3,712.6       456.5         1,034     3,463.3   487.0   197       3,505.2   366.0   4,909     3,514.3   455.7   8,005   3,538.7   455.5            
  255                                                          2,348.8   477.1     739       2,459.5   645.8     None          146           1,641.4   522.1     208     2,543.1   536.8     1,348   2,362.9   587.4                                                
  Birth length (cm)                                            892       50.4      1.9       NA        NA        1,034         50.7          2.2       192       34.7    1.4       4,004     51.0    2.1       6,122     50.4    2.1                                
  253                                                          45.0      2.9       None      146       28.4      3.5           152           47.3      2.5       551     41.3      3.0                                                                              
  ***Male/Female***[^c^](#t001fn003){ref-type="table-fn"}      606/564   503/506   908/831   550/539   189/154   2,690/2,694   5,446/5,288                                                                                                                          

^a^In HAPO, maternal FPG was measured between 24--32 weeks of gestation. In ALSPAC, the FPG was measured 18 years after pregnancy.

^b^Descriptive statistics of pregnancy outcomes were calculated in term (≥38 weeks, upper row) and preterm infants (\<37 weeks, lower row) separately. There were no preterm infants in the HAPO data set.

^c^Number of male and female infants.

**Abbreviations:** ALSPAC, The Avon Longitudinal Study of Parents and Children; BMI, body mass index; DBP, diastolic blood pressure; DNBC, The Danish National Birth Cohort; FIN, The Finnish birth data set; FPG, fasting plasma glucose; GPN, The Genomic and Proteomic Network for Preterm Birth Research; HAPO, The Hyperglycemia and Adverse Pregnancy Outcome Study; MoBa, The Mother Child data set of Norway; NA, not available; SBP, systolic blood pressure; SD, standard deviation.

Because gestational duration is a key determinant of birth weight and birth size, we only included pregnancies with spontaneous deliveries and excluded mother--child pairs without gestational duration information. Pregnancies with known gestational or fetal complications and pre-existing medical conditions were excluded. Detailed inclusion/exclusion criteria are provided in Supplementary Methods ([S1 Text](#pmed.1003305.s002){ref-type="supplementary-material"}). Preterm birth was defined as birth before 37 completed weeks of pregnancy.

This study involves reanalysis of existing data sets, and the proposed analytical aims are consistent with the original consent agreements under which the genomic and phenotypic data were obtained. Therefore, additional ethics approval was not required.

Genotype data {#sec010}
-------------

Genome-wide SNP data were generated using either Affymetrix 6.0 (Affymetrix, Santa Clara, CA, USA) or various Illumina genotyping arrays (Illumina, San Diego, CA, USA). Standardized genotype quality control procedures were applied to all data sets. Participants of non-European ancestry were identified and excluded using principal components analysis (PCA) ([S1 Text](#pmed.1003305.s004){ref-type="supplementary-material"} and [S1 Fig](#pmed.1003305.s023){ref-type="supplementary-material"}). Genome-wide imputation was performed using Minimac3 \[[@pmed.1003305.ref036]\] and the reference haplotypes from phase 3 of the 1000 Genomes Project \[[@pmed.1003305.ref037]\]. In each data set, the haplotype phasing was done in all maternal and fetal samples using Shapeit2 \[[@pmed.1003305.ref038]\]. This program accommodates mother--child relationship and accurately estimates mother--child allele transmission when phasing mother--child duos together.

Construction of genetic scores {#sec011}
------------------------------

We constructed weighted genetic scores to instrument various maternal phenotypes using GWA SNPs and their estimated effect sizes reported by the most recent large GWA studies ([S1 Text](#pmed.1003305.s004){ref-type="supplementary-material"} and [S2 Table](#pmed.1003305.s005){ref-type="supplementary-material"}). Specifically, 2,130 height-associated SNPs and 628 BMI-associated SNPs reported by the GIANT consortium \[[@pmed.1003305.ref039]\] were used to build genetic scores for height and BMI, respectively. Eight hundred thirty-one SNPs associated with BP \[[@pmed.1003305.ref040]\] were used to build genetic scores for BP. For simplicity, we built a score for average BP using the mean estimated effects of SBP and diastolic BP (DBP). For FPG, we used 22 SNPs associated with FPG levels identified in individuals without diabetes \[[@pmed.1003305.ref041]\]. We also constructed a T2D genetic score using 306 T2D SNPs \[[@pmed.1003305.ref042]\] (excluding SNPs overlapping or in close linkage disequilibrium with the 22 FPG SNPs) ([S1 Text](#pmed.1003305.s004){ref-type="supplementary-material"} and [S2 Table](#pmed.1003305.s005){ref-type="supplementary-material"}). To examine the associations of fetal growth (as proxied by birth weight) with pregnancy outcomes and maternal BP and FPG during pregnancy, we constructed genetic scores using 86 SNPs associated with birth weight with confirmed fetal effect \[[@pmed.1003305.ref027]\]. The lists of these GWA SNPs used in constructing genetic scores are provided in [S1 Data](#pmed.1003305.s003){ref-type="supplementary-material"}.

For each set of GWA SNPs, we constructed 2 genotype genetic scores: *S*~mat~ (maternal genotype score), *S*~fet~ (fetal genotype score), and 3 haplotype genetic scores: *S*~h1~, *S*~h2~, and *S*~h3~, respectively, based on the maternal transmitted (h1), maternal nontransmitted (h2), and paternal transmitted alleles (h3) ([Fig 2](#pmed.1003305.g002){ref-type="fig"}). It follows that *S*~mat~ = *S*~h1~ + *S*~h2~ and *S*~fet~ = *S*~h1~ + *S*~h3~.

Statistical analyses {#sec012}
--------------------

### Phenotype associations and instrumental strength of genetic scores {#sec013}

We first assessed the associations between the 4 maternal phenotypes (*X*) (i.e., height, BMI, BP, and FPG) and each pregnancy outcome (*Y*) (i.e., gestational duration, preterm birth, birth weight, and birth length) using regression analyses. Maternal age, fetal sex, maternal height, and prepregnancy BMI were included as covariates. Because gestational duration influences birth weight and length in a nonlinear fashion, the first 3 orthogonal polynomials of gestational duration were included as covariates in the analysis of birth weight and length. These analytical models are described in more detail in the Supplementary Methods ([S1 Text](#pmed.1003305.s002){ref-type="supplementary-material"}).

The instrumental strength of the genetic scores was checked by the variance in a maternal phenotype explained (*R*^2^) by the corresponding genetic scores.

### Association tests between haplotype genetic scores and pregnancy outcomes {#sec014}

Associations between the haplotype genetic scores and the pregnancy outcomes were tested using regression models like those used in the association analysis described above, except that the maternal phenotypes (*X*) were replaced by their corresponding 3 haplotype genetic scores (*S*~h1~ + *S*~h2~ + *S*~h3~). The associations between these haplotype scores can differentiate between maternal and fetal genetic effects ([Fig 2](#pmed.1003305.g002){ref-type="fig"}). Specifically, an association of *S*~h2~ (maternal nontransmitted haplotype score) with a pregnancy outcome suggests a maternal (intrauterine phenotypic) effect, whereas an association of *S*~h3~ (paternal transmitted haplotype score) with the pregnancy outcomes suggests fetal genetic effects. The 3 haplotype genetic scores of the same mother--child pairs (*S*~h1~, *S*~h2~, and *S*~h3~) were simultaneously tested in a single-regression model (i.e., *Y* is modeled as a function of *S*~h1~ + *S*~h2~ + *S*~h3~ + Cov, where Cov is a list of appropriate covariates), and hence, they had exactly the same sample size. Therefore, the effect size estimates of these haplotype scores and their associated *p*-values can be directly compared to assess the directions and relative contributions of the maternal and fetal effects.

### Modeling of maternal and fetal genetic effects {#sec015}

Whereas *S*~h2~ and *S*~h3~ can be used to draw inference about maternal and fetal genetic effects, this question can be addressed with greater statistical power by also including *S*~h1~, the maternal transmitted haplotype score, in the model. Thus, we modeled the maternal effect and fetal genetic effect as different linear combinations of the regression coefficients of the 3 haplotype genetic scores ([Fig 2](#pmed.1003305.g002){ref-type="fig"} and [S1 Text](#pmed.1003305.s002){ref-type="supplementary-material"}) \[[@pmed.1003305.ref030]\]. Under the assumptions of additivity between maternal and fetal effect and zero parent-of-origin effect, the total effect (*β*~h1~) of the maternal transmitted haplotype (h1) should be equal to the summation of the maternal effect (*β*~h2~) of the nontransmitted haplotype (h2) and fetal genetic effect (*β*~h3~) of the paternal transmitted haplotype (h3). Thus, (*β*~h1~−*β*~h3~) and (*β*~h1~−*β*~h2~), respectively, represent the maternal effect and the fetal genetic effect of the maternal transmitted haplotype (h1). Therefore, the average maternal effect (*β*~*MY*~) of the 2 maternal haplotypes on a birth outcome (*Y*) can be expressed as (*β*~h1~−*β*~h3~+ *β*~h2~)/2, and the average fetal genetic effect (*β*~*FY*~) of the maternal and paternal transmitted haplotypes can be expressed as (*β*~h1~−*β*~h2~+ *β*~h3~)/2. Because these linear combinations also capture the maternal or fetal genetic effects of the maternal transmitted haplotype (h1), they are more powerful than the methods only using the maternal nontransmitted haplotype (h2) or the paternal transmitted haplotype (h3) as instruments, respectively, for maternal effect and fetal genetic effect.

### Estimation of maternal causal effects {#sec016}

The estimated maternal effect (${\hat{\beta}}_{MY}$) from the haplotype genetic score association analyses can be interpreted as the amount of change in a pregnancy outcome (*Y*) caused by a certain amount of difference in a maternal phenotype (*X*) associated with one-unit genetic score. The maternal causal effect (${\hat{\beta}}_{XY}^{m}$) was estimated using the ratio estimate \[[@pmed.1003305.ref043]\] (${\hat{\beta}}_{MY}/{\hat{\beta}}_{MX}$), where ${\hat{\beta}}_{MX}$ is the estimated maternal effect on the maternal phenotype ([Fig 2](#pmed.1003305.g002){ref-type="fig"}). As an alternative, we also performed instrumental variable analysis using the two-stage least-squares (TSLS) approach \[[@pmed.1003305.ref043]\], with the maternal nontransmitted haplotype score (*S*~h2~) as the genetic instrument for maternal causal effect \[[@pmed.1003305.ref015]\].

### Estimation of genetically confounded associations {#sec017}

The fetal genetic effect (*β*~*FY*~) reflects that the genetic variants associated with an adult phenotype (*X*′) in the offspring or the corresponding maternal phenotype (*X*) have direct fetal genetic effect on a pregnancy outcome (*Y*). This shared genetic effect can confound the association between a maternal phenotype (*X*) and a pregnancy outcome (*Y*), as well as the association between the pregnancy outcome (*Y*) and the adult phenotype (*X*′) in offspring ([Fig 1](#pmed.1003305.g001){ref-type="fig"}).

By assuming that all the genetic variants associated with an adult phenotype in offspring (*X*′) or the corresponding maternal phenotype (*X*) have a similar effect on a pregnancy outcome (*Y*) as the fetal genetic effect estimated from the genetic score built on known GWA SNPs (${\hat{\beta}}_{FY}$), we can approximately estimate the magnitude of these genetically confounded associations (see [S1 Text](#pmed.1003305.s002){ref-type="supplementary-material"} for details). Specifically, the genetically confounded association between a maternal phenotype (*X*) and a pregnancy outcome (*Y*) due to the shared genetic effect can be estimated by $${\hat{\beta}}_{XY}^{c} = \frac{h_{X}^{2}}{2}\frac{{\hat{\beta}}_{FY}}{{\hat{\beta}}_{MX}},$$ where ${\hat{\beta}}_{MX}$ is estimated maternal effect and $h_{X}^{2}$ is the heritability (the proportion of additive genetic variance) of the maternal phenotype (*X*).

Similarly, the genetically confounded association between a pregnancy outcome (*Y*) and an adult (late) phenotype (*X*′) in offspring can be estimated by $${\hat{\beta}}_{YX^{\prime}}^{c} = h^{2}\frac{Var\left( X^{\prime} \right)}{Var\left( Y \right)}\left( {\frac{{\hat{\beta}}_{MY}}{2} + \hat{\beta}}_{FY} \right)$$ and $${\hat{\beta}}_{YX^{\prime}}^{c} = h^{2}\frac{Var\left( X^{\prime} \right)}{Var\left( Y \right)}\left( \frac{\hat{\beta_{h1}+\beta_{h3}}}{2} \right),$$ where *h*^2^ is the heritability of the adult phenotype and Var(*X*′) and Var(*Y*) are, respectively, the variance of the adult phenotype and the variance of the pregnancy outcome. The first method ([Method 1](#pmed.1003305.e014){ref-type="disp-formula"}) can partition the confounded association into the maternal ($\frac{\beta_{MY}}{2}$) and the fetal component (*β*~*FY*~) ([S1 Text](#pmed.1003305.s002){ref-type="supplementary-material"}).

### Multivariable MR analysis {#sec018}

The genetic scores built on hundreds or thousands of SNPs are likely to be less specific because they are more likely to be associated with other phenotypic traits \[[@pmed.1003305.ref044]\], which can introduce ambiguities in the interpretation of genetic score associations \[[@pmed.1003305.ref045]\]. To circumvent this issue, we performed a two-sample multivariable MR analysis \[[@pmed.1003305.ref046], [@pmed.1003305.ref047]\] using the MR pleiotropy residual sum and outlier (MR-PRESSO) \[[@pmed.1003305.ref048]\] to detect and correct for variants with horizontal pleiotropic effects \[[@pmed.1003305.ref049]\] in multiple-variant MR testing. Three MR-PRESSO tests were applied: the global test was used to detect the presence of horizontal pleiotropy, the outlier test to identify variants with significant horizontal pleiotropic effect, and the distortion test to estimate the distortion caused by significant horizontal pleiotropic outlier variants. This analysis studies the maternal or fetal genetic effects by testing whether the effects of the maternal transmitted (h1), maternal nontransmitted (h2), and paternal transmitted (h3) alleles of the GWA SNPs on a pregnancy outcome are proportional to their reported effects on an adult phenotype (*X*′) in the reference GWA studies ([S1 Text](#pmed.1003305.s023){ref-type="supplementary-material"} and [S4 Fig](#pmed.1003305.s026){ref-type="supplementary-material"}). The allele-specific effect estimates (for the h1, h2, and h3 alleles) of each SNP on a pregnancy outcome were obtained using the same regression methods for haplotype genetic score analysis ([S1 Text](#pmed.1003305.s002){ref-type="supplementary-material"}).

We did meta-analyses of the results from all available data sets to generate the overall results. Fixed-effect meta-analysis was used to combine the regression coefficients and standard errors from individual studies, and we checked between-study heterogeneity using Cochran's Q test. The meta-analyses were done using the R metafor package \[[@pmed.1003305.ref050]\].

Results {#sec019}
=======

Phenotypic associations between maternal phenotypes and pregnancy outcomes {#sec020}
--------------------------------------------------------------------------

We used 10,734 mother--infant pairs with both genotype and phenotype data in our analyses ([S1 Table](#pmed.1003305.s004){ref-type="supplementary-material"}). Distributions of key variables for the maternal phenotypes and pregnancy outcomes are shown in [Table 1](#pmed.1003305.t001){ref-type="table"} and [S5](#pmed.1003305.s027){ref-type="supplementary-material"}--[S7](#pmed.1003305.s029){ref-type="supplementary-material"} Figs.

The meta-analysis across the 6 data sets showed that taller maternal height was associated with longer gestational duration (0.14 day/cm, 95% CI: 0.10 to 0.18, *p* = 2.2 × 10^−12^), lower preterm birth risk (OR = 0.97 /cm, 95% CI: 0.96 to 0.98, *p* = 2.2 × 10^−9^), and higher birth weight (15 g/cm, 95% CI: 13.7 to 16.3, *p* = 1.5 × 10^−111^) and length (0.068 cm/cm, 95% CI: 0.061 to 0.075, *p* = 1.6 × 10^−75^). Maternal BMI was positively associated with birth weight (15.6 g/\[kg/m^2^\], 95% CI: 13.5 to 17.7, *p* = 1.0 × 10^−47^) and birth length (0.05 cm/\[kg/m^2^\], 95% CI: 0.04 to 0.06, *p* = 3.9 × 10^−15^) but was not associated with gestational duration (0.05 day per kg/m^2^, 95% CI: −0.01 to 0.11, *p* = 0.12) or preterm birth risk (OR = 0.99 per kg/m^2^, 95% CI: 0.98 to 1.01, *p* = 0.42) ([S3 Table](#pmed.1003305.s006){ref-type="supplementary-material"}).

Using data from ALSPAC and HAPO, we observed that maternal BP during pregnancy was negatively associated with gestational duration and birth weight. The estimated effect sizes on gestational duration by SBP and DBP were −0.04 day/mmHg (95% CI: −0.08 to −0.01, *p* = 7.3 × 10^−3^) and −0.11 day/mmHg (95% CI: −0.15 to −0.06, *p* = 3.3 × 10^−6^), respectively. The estimated effect sizes on birth weight by SBP and DBP were −3.0 g/mmHg (95% CI: −4.6 to −1.5, *p* = 1.8 × 10^−4^) and −6.2 g/mmHg (95% CI: −8.4 to −3.9, *p* = 6.0 × 10^−8^), respectively. In HAPO, there was a strong positive association between maternal FPG and birth weight (192 g/\[mmol/L\], 95% CI: 116 to 268, *p* = 5.7 × 10^−7^) and birth length (0.62 cm/\[mmol/L\], 95% CI: 0.27 to 0.97, *p* = 4.8 × 10^−4^). However, the association between FPG measured 18 years after pregnancy with either birth weight or length in the ALSPAC data set was close to zero with wide confidence intervals ([S3 Table](#pmed.1003305.s006){ref-type="supplementary-material"}).

Associations between genetic scores and maternal phenotypes {#sec021}
-----------------------------------------------------------

We examined the instrumental strength of the genetic scores for the various maternal phenotypes. The maternal genotype genetic scores (*S*~mat~) were associated with the corresponding maternal phenotypes and explained a substantial fraction of the phenotypic variances with similar contributions from the transmitted (h1) or the nontransmitted haplotype scores (h2) ([S4 Table](#pmed.1003305.s007){ref-type="supplementary-material"}).

The maternal height genotype score (*S*~mat~) explained \>20% of the maternal height variance ([S5 Table](#pmed.1003305.s008){ref-type="supplementary-material"}), and the maternal BMI genotype score (*S*~mat~) explained approximately 5% of the maternal BMI variance ([S6 Table](#pmed.1003305.s009){ref-type="supplementary-material"}). The BP genotype scores explained over 2% variance in maternal BP ([S7 Table](#pmed.1003305.s010){ref-type="supplementary-material"}), which is less than half of the reported fraction of variance explained by the same score (5.7%) in a published GWA study of nonpregnant women and men (generally of an older age than pregnant women) \[[@pmed.1003305.ref040]\], suggesting that these BP SNPs have a larger effect on BP in older populations or a weaker effect on maternal BP during pregnancy.

In HAPO, the maternal FPG genetic score built on 22 SNPs explained 8.3% of the FPG variance measured between 24--32 weeks. In ALSPAC, the same score explained 4.1% of the variance of FPG measured 18 years after pregnancy. By contrast, the T2D score (306 SNPs) explained much less FPG variance ([S8 Table](#pmed.1003305.s011){ref-type="supplementary-material"}).

For each phenotype, we checked the correlations among the various genotype and haplotype genetic scores ([S9 Table](#pmed.1003305.s012){ref-type="supplementary-material"}). For height, we observed significant correlations between the maternal genotype (*S*~mat~) and the paternal transmitted haplotype score (*S*~h3~) and between the maternal transmitted (*S*~h1~) and nontransmitted scores (*S*~h2~), indicating assortative mating \[[@pmed.1003305.ref015], [@pmed.1003305.ref051], [@pmed.1003305.ref052]\] and increased homozygosity of height-associated SNPs.

Maternal causal effects and genetically confounded associations between maternal phenotypes and birth outcomes {#sec022}
--------------------------------------------------------------------------------------------------------------

We next utilized haplotype genetic scores as genetic instruments to dissect the maternal and fetal genetic effects underlying the observed associations between maternal phenotypes and pregnancy outcomes ([Table 2](#pmed.1003305.t002){ref-type="table"}). Detailed meta-analysis of individual data sets can be found in [S8](#pmed.1003305.s030){ref-type="supplementary-material"}--[S12](#pmed.1003305.s034){ref-type="supplementary-material"} Figs. We also conducted random-effects meta-analyses ([S10 Table](#pmed.1003305.s013){ref-type="supplementary-material"}), and the results were essentially the same as the results obtained by fixed-effect meta-analyses ([Table 2](#pmed.1003305.t002){ref-type="table"}). To further check the robustness of the results, we conducted the analyses separately in ALSPAC ([S11 Table](#pmed.1003305.s014){ref-type="supplementary-material"}) and the other 5 data sets ([S12 Table](#pmed.1003305.s015){ref-type="supplementary-material"}). The results were similar, except the 5 data sets showed more associations with preterm birth, probably because these data sets had more preterm pregnancies. Based on the estimated maternal and fetal genetic effects, we estimated the maternal causal effects and genetically confounded associations between maternal phenotypes and birth outcomes due to shared genetics (Methods and [Fig 3](#pmed.1003305.g003){ref-type="fig"}).

![**Observed phenotypic associations, estimated maternal causal effects, fetal genetic effects, and genetically confounded associations per 1-SD change in maternal traits on gestational duration (left) and birth weight (adjusted by gestational duration) (right).** The 1-SD values for maternal traits are 6.4 cm (height), 4.0 kg/m^2^ (BMI), 5.8 mmHg (BP), and 0.36 mmol/L (FPG). \* indicates birth weight adjusted by gestational duration. BMI, body mass index; BP, blood pressure; FPG, fasting plasma glucose; SD, standard deviation.](pmed.1003305.g003){#pmed.1003305.g003}

10.1371/journal.pmed.1003305.t002

###### Association between haplotype genetic scores and birth outcomes.

![](pmed.1003305.t002){#pmed.1003305.t002g}

  Maternal Trait (Unit) Haplotype Score Tests[^a^](#t002fn001){ref-type="table-fn"}   Gestational Days   Preterm Birth (log\[OR\])   Birth Weight (g)                               Birth Length (cm)                                                                                                                                                       
  ----------------------------------------------------------------------------------- ------------------ --------------------------- ---------------------------------------------- ------------------- -------- ---------------------------------------------------- ------ ----- ----------------------------------------------------- --------- -------- -----------------------------------------------------
  **Height (cm)**                                                                                                                                                                                                                                                                                                                                           
  *Maternal transmitted (β*~*h1*~*)*                                                  0.038              0.046                       0.41                                           −0.027              0.011    0.016[\*](#t002fn004){ref-type="table-fn"}           20     1.6   6.10 × 10^−38^[\*](#t002fn004){ref-type="table-fn"}   0.097     0.0087   1.10 × 10^−28^[\*](#t002fn004){ref-type="table-fn"}
  *Maternal nontransmitted (β*~*h2*~*)*                                               0.17               0.047                       0.00022[\*](#t002fn004){ref-type="table-fn"}   −0.037              0.011    0.00097[\*](#t002fn004){ref-type="table-fn"}         6.3    1.6   7.60 × 10^−5^[\*](#t002fn004){ref-type="table-fn"}    0.022     0.0088   0.011[\*](#t002fn004){ref-type="table-fn"}
  *Paternal transmitted (β*~*h3*~*)*                                                  −0.041             0.046                       0.37                                           0.023               0.011    0.038[\*](#t002fn004){ref-type="table-fn"}           14     1.6   3.10 × 10^−19^[\*](#t002fn004){ref-type="table-fn"}   0.074     0.0085   4.70 × 10^−18^[\*](#t002fn004){ref-type="table-fn"}
  *Maternal effect (β*~*MY*~*)*                                                       0.13               0.04                        0.0017[\*](#t002fn004){ref-type="table-fn"}    −0.044              0.0098   9.00 × 10^−6^[\*](#t002fn004){ref-type="table-fn"}   6.3    1.4   5.20 × 10^−6^[\*](#t002fn004){ref-type="table-fn"}    0.022     0.0076   0.0033[\*](#t002fn004){ref-type="table-fn"}
  *Fetal effect (β*~*FY*~*)*                                                          −0.089             0.041                       0.029[\*](#t002fn004){ref-type="table-fn"}     0.016               0.0099   0.1                                                  14     1.4   1.10 × 10^−23^[\*](#t002fn004){ref-type="table-fn"}   0.074     0.0076   2.70 × 10^−22^[\*](#t002fn004){ref-type="table-fn"}
  **BMI (kg/m**^**2**^**)**                                                                                                                                                                                                                                                                                                                                 
  *Maternal transmitted (β*~*h1*~*)*                                                  −0.059             0.17                        0.73                                           −0.065              0.041    0.11                                                 23     5.8   7.00 × 10^−5^[\*](#t002fn004){ref-type="table-fn"}    0.066     0.032    0.038[\*](#t002fn004){ref-type="table-fn"}
  *Maternal nontransmitted (β*~*h2*~*)*                                               −0.11              0.17                        0.52                                           0.015               0.041    0.71                                                 8.8    5.8   0.13                                                  0.079     0.032    0.013[\*](#t002fn004){ref-type="table-fn"}
  *Paternal transmitted (β*~*h3*~*)*                                                  0.027              0.17                        0.88                                           0.049               0.04     0.23                                                 −6.5   5.7   0.26                                                  0.027     0.032    0.39
  *Maternal effect (β*~*MY*~*)*                                                       −0.098             0.15                        0.51                                           −0.048              0.036    0.18                                                 19     5     0.00016[\*](#t002fn004){ref-type="table-fn"}          0.06      0.028    0.031[\*](#t002fn004){ref-type="table-fn"}
  *Fetal effect (β*~*FY*~*)*                                                          0.043              0.15                        0.77                                           −0.018              0.036    0.6                                                  4      5     0.43                                                  0.0077    0.028    0.78
  **BP**[^**b**^](#t001fn003){ref-type="table-fn"} **(mmHg)**                                                                                                                                                                                                                                                                                               
  *Maternal transmitted (β*~*h1*~*)*                                                  −0.22              0.064                       0.00067[\*](#t002fn004){ref-type="table-fn"}   0.034               0.015    0.027[\*](#t002fn004){ref-type="table-fn"}           −6.8   2.2   0.0016[\*](#t002fn004){ref-type="table-fn"}           −0.018    0.012    0.13
  *Maternal nontransmitted (β*~*h2*~*)*                                               −0.035             0.064                       0.59                                           0.047               0.016    0.0023[\*](#t002fn004){ref-type="table-fn"}          −3.1   2.2   0.16                                                  −0.018    0.012    0.13
  *Paternal transmitted (β*~*h3*~*)*                                                  −0.016             0.064                       0.8                                            0.005               0.015    0.74                                                 −5.9   2.1   0.0053[\*](#t002fn004){ref-type="table-fn"}           −0.017    0.012    0.15
  *Maternal effect (β*~*MY*~*)*                                                       −0.12              0.055                       0.033[\*](#t002fn004){ref-type="table-fn"}     0.038               0.013    0.0045[\*](#t002fn004){ref-type="table-fn"}          −2     1.9   0.27                                                  −0.0096   0.01     0.35
  *Fetal effect (β*~*FY*~*)*                                                          −0.1               0.056                       0.075                                          −0.0035             0.013    0.8                                                  −4.8   1.9   0.0094[\*](#t002fn004){ref-type="table-fn"}           −0.0086   0.01     0.4
  **FPG (mmol/L)**                                                                                                                                                                                                                                                                                                                                          
  *Maternal transmitted (β*~*h1*~*)*                                                  −3.9               1.8                         0.029[\*](#t002fn004){ref-type="table-fn"}     0.6                 0.43     0.16                                                 13     59    0.82                                                  −0.067    0.32     0.84
  *Maternal nontransmitted (β*~*h2*~*)*                                               −3.2               1.8                         0.071                                          0.54                0.43     0.21                                                 270    59    4.70 × 10^−6^[\*](#t002fn004){ref-type="table-fn"}    0.71      0.32     0.029[\*](#t002fn004){ref-type="table-fn"}
  *Paternal transmitted (β*~*h3*~*)*                                                  2.7                1.7                         0.12                                           −0.38               0.43     0.37                                                 −52    59    0.38                                                  −0.13     0.32     0.69
  *Maternal effect (β*~*MY*~*)*                                                       −5                 1.5                         0.0012[\*](#t002fn004){ref-type="table-fn"}    0.77                0.37     0.039[\*](#t002fn004){ref-type="table-fn"}           170    51    0.0011[\*](#t002fn004){ref-type="table-fn"}           0.37      0.28     0.19
  *Fetal effect (β*~*FY*~*)*                                                          0.99               1.5                         0.51                                           −0.14               0.36     0.7                                                  −150   50    0.0022[\*](#t002fn004){ref-type="table-fn"}           −0.46     0.28     0.096
  **T2D (log\[OR\])**                                                                                                                                                                                                                                                                                                                                       
  *Maternal transmitted (β*~*h1*~*)*                                                  0.013              0.3                         0.97                                           −0.0079             0.074    0.91                                                 −14    10    0.17                                                  −0.065    0.056    0.25
  *Maternal nontransmitted (β*~*h2*~*)*                                               0.05               0.31                        0.87                                           0.013               0.072    0.86                                                 33     10    0.0012[\*](#t002fn004){ref-type="table-fn"}           0.059     0.057    0.3
  *Paternal transmitted (β*~*h3*~*)*                                                  0.83               0.31                        0.0069[\*](#t002fn004){ref-type="table-fn"}    −0.11               0.073    0.13                                                 −28    10    0.0061[\*](#t002fn004){ref-type="table-fn"}           −0.033    0.057    0.56
  *Maternal effect (β*~*MY*~*)*                                                       −0.39              0.27                        0.15                                           0.058               0.063    0.36                                                 24     8.9   0.0064[\*](#t002fn004){ref-type="table-fn"}           0.015     0.049    0.76
  *Fetal effect (β*~*FY*~*)*                                                          0.4                0.27                        0.14                                           −0.067              0.062    0.28                                                 −39    8.8   1.30 × 10^−5^[\*](#t002fn004){ref-type="table-fn"}    −0.085    0.049    0.082

^a^*β*~h1~, *β*~h2~, and *β*~h3~ are the effects of the 3 haplotype genetic scores. *β*~*MY*~ = (*β*~h1~ − *β*~h3~ + *β*~h2~)/2 and *β*~*FY*~ = (*β*~h1~ − *β*~h2~ + *β*~h3~)/2 are, respectively, the maternal and fetal genetic effects modeled by linear combinations of the haplotype effects.

^b^BP: mean of the SBP and DBP scores.

^c^Beta: estimated effects of genetic score associations given by per unit change in genetic scores of the maternal traits.

\**p*-Values less than 0.05.

**Abbreviations:** BMI, body mass index; BP, blood pressure; DBP, diastolic BP; SBP, systolic BP; SE, standard error; T2D, type 2 diabetes.

### Maternal height {#sec023}

The maternal nontransmitted height genetic score (*S*~h2~) was positively associated with gestational duration (*p* = 2.2 × 10^−4^) and negatively associated with preterm birth (*p* = 9.7 × 10^−4^) ([Table 2](#pmed.1003305.t002){ref-type="table"}). The ratio estimates showed a maternal causal effect of approximately 1.0 days (95% CI: 0.38 to 1.64, *p* = 1.8 × 10^−3^) longer gestation per 1-standard deviation (SD) (6.4 cm) increase in maternal height. This effect was offset by a weaker and opposite fetal genetic effect of 0.71 days' (95% CI: 0.07 to 1.35, *p* = 2.9 × 10^−2^) shorter gestation per the same amount of genetic score associated with a 1-SD increase in maternal height ([Fig 3](#pmed.1003305.g003){ref-type="fig"} and [S13 Table](#pmed.1003305.s016){ref-type="supplementary-material"}).

Maternal and paternal transmitted haplotype scores (*S*~h1~ and *S*~h3~) for height were positively associated with birth weight and birth length. The maternal nontransmitted score (*S*~h2~) was also positively associated with birth weight and length, but the effect estimates were smaller than the transmitted haplotype scores ([Table 2](#pmed.1003305.t002){ref-type="table"}). The larger effects of transmitted alleles indicate height-associated SNPs can influence growth in early prenatal development through fetal genetic effect. The estimates for maternal causal and fetal genetic effects were 50 g (95% CI: 29 to 72, *p* = 5.6 × 10^−6^) and 111 g (95% CI: 89 to 133, *p* = 5.0 × 10^−23^), respectively, for birth weight and 0.18 cm (95% CI: 0.06 to 0.30, *p* = 3.3 × 10^−3^) and 0.59 cm (95% CI: 0.47 to 0.71, *p* = 1.0 × 10^−21^) for birth length per genetic alleles associated with a 1-SD (6.4 cm) increase in maternal height ([Fig 3](#pmed.1003305.g003){ref-type="fig"}, [S13 Fig](#pmed.1003305.s035){ref-type="supplementary-material"}, and [S13 Table](#pmed.1003305.s016){ref-type="supplementary-material"}).

### Maternal prepregnancy BMI {#sec024}

BMI haplotype genetic scores were not significantly associated with gestational duration or preterm birth ([Table 2](#pmed.1003305.t002){ref-type="table"}), and the ratio estimates of maternal causal effects on gestational duration (−0.45 day, 95% CI: −1.80 to 0.89, *p* = 0.51) and preterm birth (OR = 0.8, 95% CI: 0.6 to 1.1, *p* = 0.18) were not significant ([S13 Table](#pmed.1003305.s016){ref-type="supplementary-material"}), suggesting both minimal maternal and fetal effect of the BMI-associated SNPs on gestational duration. Linear hypotheses modeling suggested that BMI-associated SNPs have some maternal and no fetal effect on birth weight and length ([Table 2](#pmed.1003305.t002){ref-type="table"}). The estimated maternal causal effect on birth weight was 88 g (95% CI: 42 to 134, *p* = 1.9 × 10^−4^) and on birth length was 0.28 cm (95% CI: 0.02 to 0.53, *p* = 3.2 × 10^−2^) per 1-SD (4.0 kg/m^2^) genetically increased BMI ([Fig 3](#pmed.1003305.g003){ref-type="fig"}, [S13 Fig](#pmed.1003305.s035){ref-type="supplementary-material"}, and [S13 Table](#pmed.1003305.s016){ref-type="supplementary-material"}).

### Maternal BP {#sec025}

There was a significant association between the maternal nontransmitted BP genetic score and increased preterm birth risk (*p* = 2.3 × 10^−3^), suggesting the association between maternal BP and gestational duration was primarily driven by a maternal effect ([Table 2](#pmed.1003305.t002){ref-type="table"}). The estimated causal effect sizes based on the ratio method were −2.3 days (95% CI: −4.4 to −0.14, *p* = 3.6 × 10^−2^) on gestational duration and OR = 2.1 (95% CI: 1.2 to 3.5, *p* = 5.7 × 10^−3^) in preterm birth risk per 1-SD (5.8 mmHg) genetically increased maternal BP ([Fig 3](#pmed.1003305.g003){ref-type="fig"}, [S13 Fig](#pmed.1003305.s035){ref-type="supplementary-material"}, and [S13 Table](#pmed.1003305.s016){ref-type="supplementary-material"}).

Both maternal transmitted and paternal transmitted BP scores were negatively associated with birth weight (*p* = 1.6 × 10^−3^ and 5.3 × 10^−3^ for *S*~h1~ and *S*~h3~, respectively; [Table 2](#pmed.1003305.t002){ref-type="table"}), suggesting the negative association between maternal BP and birth weight was mainly caused by a fetal genetic effect. The estimated fetal genetic effect was a reduction of 94 g (95% CI: 21 to 166, *p* = 1.1 × 10^−2^) in birth weight by alleles associated with a 1-SD (5.8 mmHg) increase in maternal BP ([Fig 3](#pmed.1003305.g003){ref-type="fig"} and [S13 Table](#pmed.1003305.s016){ref-type="supplementary-material"}).

### Maternal FPG {#sec026}

We observed a positive association between maternal nontransmitted FPG genetic score (*S*~h2~) and birth weight (*p* = 4.7 × 10^−6^), indicating a strong causal effect of increased maternal FPG level on higher birth weight ([Table 2](#pmed.1003305.t002){ref-type="table"}). In the HAPO data set, the estimated causal effect size by TSLS based on (*S*~h2~) was 147 g (95% CI: 15 to 279, *p* = 3.0 × 10^−2^) per 1-SD (0.36 mmol/L) increase in maternal FPG, and the ratio estimate in all mother--child pairs was 59 g (95% CI: 22 to 96, *p* = 1.8 × 10^−3^) ([S13 Table](#pmed.1003305.s016){ref-type="supplementary-material"}). Interestingly, but not unexpectedly, the linear modeling showed a negative fetal genetic effect of FPG increasing alleles on birth weight (−54 g, 95% CI: −90 to −18, *p* = 3.3 × 10^−3^). The linear hypothesis modeling also showed a significant negative maternal effect of high maternal FPG on gestational duration (−1.7 days, 95% CI: −2.8 to −0.6, *p* = 2.0 × 10^−3^) and increased risk for preterm birth (OR = 1.3, 95% CI: 1.0 to 1.7, *p* = 4.3 × 10^−2^) per 1-SD (0.36 mmol/L) increase in maternal FPG ([Fig 3](#pmed.1003305.g003){ref-type="fig"}, [S13 Fig](#pmed.1003305.s035){ref-type="supplementary-material"}, and [S13 Table](#pmed.1003305.s016){ref-type="supplementary-material"}).

To further understand whether the observed associations were driven by the SNPs that influence normal FPG levels or by the SNPs associated with pathological hyperglycemia (i.e., T2D), we tested associations between the T2D haplotype scores and pregnancy outcomes. Compared to the FPG scores, the maternal nontransmitted T2D score (*S*~h2~) was less significantly associated with both birth weight and gestational duration, but the negative associations between the paternal transmitted score (*S*~h3~) and birth weight and gestational duration were more apparent ([Table 2](#pmed.1003305.t002){ref-type="table"}).

As shown in [Fig 3](#pmed.1003305.g003){ref-type="fig"} and [S13 Fig](#pmed.1003305.s035){ref-type="supplementary-material"}, the combinations of the estimated maternal causal effects and the genetically confounded associations due to genetic transmission were consistent with the observed phenotypic associations between maternal phenotypes and birth outcomes. The maternal causal effects were usually more dominant than the genetically confounded associations in shaping the phenotypic associations between maternal phenotypes and birth outcomes. In some cases, the maternal causal effects and the genetically confounded associations pointed to opposite directions (for example, between height and gestational duration and between FPG and birth weight), and in these situations, the estimated maternal causal effects could be larger than the observed phenotypic associations.

Genetically confounded associations between birth outcomes and adult phenotypes in offspring {#sec027}
--------------------------------------------------------------------------------------------

We estimate the magnitude of genetically confounded associations between the birth outcomes and adult phenotypes (in the offspring) based on the hypothesis that the association was driven by the variants that were associated with an adult phenotype were also associated with a birth outcome (Methods). The 2 methods ([Method 1](#pmed.1003305.e014){ref-type="disp-formula"} and [Method 2](#pmed.1003305.e015){ref-type="disp-formula"}) generated similar results ([S14 Table](#pmed.1003305.s017){ref-type="supplementary-material"}). As shown in [Fig 4](#pmed.1003305.g004){ref-type="fig"} and [S14 Table](#pmed.1003305.s017){ref-type="supplementary-material"}, a 1-SD change in birth weight (gestational-age--adjusted) was estimated to be associated with 0.20 SD (95% CI: 0.17 to 0.24, *p* = 3.4 × 10^−28^) and 0.076 SD (95% CI: 0.014 to 0.138, *p* = 1.6 × 10^−2^) differences, respectively, in adult height and BMI. One-SD increases in both gestational duration and birth weight were estimated to be associated with a 0.05 SD decrease in adult BP and a 0.025--0.03 SD decrease in adult FPG level, and birth weight was also estimated to be negatively associated with susceptibility to T2D (OR = 0.91, 95% CI: 0.85 to 0.98, *p* = 7.3 × 10^−3^). The genetically confounded associations between birth outcomes and adult phenotypes ([S14 Fig](#pmed.1003305.s036){ref-type="supplementary-material"} and [S15 Fig](#pmed.1003305.s037){ref-type="supplementary-material"}) were mainly driven by the shared genetic effects in offspring; however, the maternal effects could substantially confound the associations and point to opposite directions to the confounded associations by fetal genetic effects in certain cases (for example, the confounded associations between gestational duration and height and between birth weight and FPG or T2D risk). We compared the genetically confounded associations between birth weight and adult phenotypes with the estimated phenotypic associations from genetic correlation \[[@pmed.1003305.ref020]\], the observed associations in the ALSPAC data, and the reported associations from an epidemiological meta-analysis \[[@pmed.1003305.ref053]\] ([Fig 5](#pmed.1003305.g005){ref-type="fig"}). The estimated genetically confounded associations using our approach were similar to those estimated from genetic correlations \[[@pmed.1003305.ref020]\] and were largely consistent with the observed or reported associations between birth weight and adult phenotypes with the exception of body height, for which the observed association (from the ALSPAC data) was significantly stronger than the estimated confounded association due to shared genetics.

![Estimated differences in adult phenotypes (in SDs) per 1-SD difference in birth weight and gestational duration.\
The birth weight was adjusted by gestational duration; 1 SD = 426 g. 1 SD of gestational duration was 11.4 days. The 1-SD values for adult phenotypes were assumed to be 6.4 cm (height), 4.0 kg/m^2^ (BMI), 6.9 mmHg (BP), 0.37 mmol/L (FPG), and 1.81 for log OR of T2D. \* indicates birth weight adjusted by gestational duration. BMI, body mass index; BP, blood pressure; FPG, fasting plasma glucose; SD, standard deviation; T2D, type 2 diabetes.](pmed.1003305.g004){#pmed.1003305.g004}

![Comparing the magnitudes of genetically confounded associations (differences in adult phenotypes \[in SDs\] per 1-SD difference in birth weight) with observed and reported phenotypic associations.\
Confounded (eff): genetically confounded associations estimated based on the fetal genetic effect on birth weight (adjusted by gestational duration) of the variants associated with an adult phenotype. Confounded (cor): genetically confounded associations between birth weight (unadjusted by gestational duration) and adult phenotype based on the reported genetic correlations \[[@pmed.1003305.ref020]\]. Observed: observed phenotypic associations between gestational-duration--adjusted birth weight and offspring height, BMI, BP, and FPG measured at age 17 in ASLPAC. Reported: the reported associations between birth weight (unadjusted by gestational duration) and BP and T2D susceptibility from a recent epidemiological study \[[@pmed.1003305.ref053]\]. One-SD values in the gestational-duration--adjusted and unadjusted birth weight were 426 g and 484 g, respectively. BMI, body mass index; BP, blood pressure; FPG, fasting plasma glucose; SD, standard deviation; T2D, type 2 diabetes.](pmed.1003305.g005){#pmed.1003305.g005}

Causal effect of fetal growth on gestational duration, maternal BP, and FPG {#sec028}
---------------------------------------------------------------------------

To test the possible fetal drive of fetal growth on birth outcomes and maternal pregnancy phenotypes, we constructed genetic scores using 86 SNPs associated with birth weight with confirmed fetal effect \[[@pmed.1003305.ref027]\] and tested their associations with birth outcomes as well as maternal BP and FPG during pregnancy (Tables [3](#pmed.1003305.t003){ref-type="table"} and [4](#pmed.1003305.t004){ref-type="table"}). The fetal genetic score for birth weight was significantly associated with gestational-age--adjusted birth weight with an *R*^2^ = 3.1%. The paternal transmitted haplotype score (*S*~h3~) consistently has larger effect than the maternal transmitted score (*S*~h1~) ([S15 Table](#pmed.1003305.s018){ref-type="supplementary-material"}), probably because of a negative maternal effect of the same alleles on birth weight and birth length, as shown by the negative effect of the nontransmitted haplotype score (*S*~h2~) ([Table 3](#pmed.1003305.t003){ref-type="table"}). The maternal and paternal transmitted birth weight haplotype scores (*S*~h1~ and *S*~h3~) were also associated with shorter gestational duration and increased preterm birth risk ([Table 3](#pmed.1003305.t003){ref-type="table"} and [S16 Fig](#pmed.1003305.s038){ref-type="supplementary-material"}). Using the paternal transmitted haplotype score as an instrument, the estimated causal effects were 3.2 days (95% CI: 1.5 to 5.0, *p* = 2.7 × 10^−4^) shorter gestation and an approximate doubling of the preterm birth risk per 1-SD changes in fetal growth rate ([Table 3](#pmed.1003305.t003){ref-type="table"}). In addition, we also observed significant associations between paternal transmitted birth weight score (*S*~h3~) and maternal SBP (*p* = 2.2 × 10^−2^) measured during pregnancy and the estimated causal effects (ratio method) were 1.4 mmHg (95% CI: 0.2 to 2.6, *p* = 2.3 × 10^−2^) increase in SBP per 1-SD changes in fetal growth rate ([Table 4](#pmed.1003305.t004){ref-type="table"} and [S17 Fig](#pmed.1003305.s039){ref-type="supplementary-material"}).

10.1371/journal.pmed.1003305.t003

###### Associations between birth weight genetic scores and birth outcomes and estimated causal effects per 1-SD change in gestational-age--adjusted birth weight.

![](pmed.1003305.t003){#pmed.1003305.t003g}

  Genetic Score Association and Causal Estimation[^a^](#t003fn001){ref-type="table-fn"}   Gestational Days   Preterm Birth (log\[OR\])   Birth Weight (g)                               Birth Length (cm)                                                                                                                                                                                                        
  --------------------------------------------------------------------------------------- ------------------ --------------------------- ---------------------------------------------- ------------------- --------- ---------------------------------------------------- ------- ------- ----------------------------------------------------- ----------------------------------------------------- --------- -----------------------------------------------------
  *Maternal transmitted (β*~*h1*~*)*                                                      −0.0056            0.0027                      0.035[\*](#t003fn002){ref-type="table-fn"}     0.0024              0.00064   0.00018[\*](#t003fn002){ref-type="table-fn"}         0.79    0.087   1.80 × 10^−19^[\*](#t003fn002){ref-type="table-fn"}   0.0018                                                0.00048   0.00022[\*](#t003fn002){ref-type="table-fn"}
  *Maternal nontransmitted (β*~*h2*~*)*                                                   0.001              0.0027                      0.7                                            −0.00058            0.00065   0.37                                                 −0.19   0.088   0.029[\*](#t003fn002){ref-type="table-fn"}            −0.00022                                              0.00049   0.66
  *Paternal transmitted (β*~*h3*~*)*                                                      −0.0099            0.0026                      0.00018[\*](#t003fn002){ref-type="table-fn"}   0.0019              0.00064   0.003[\*](#t003fn002){ref-type="table-fn"}           1.3     0.087   1.70 × 10^−48^[\*](#t003fn002){ref-type="table-fn"}   0.0031                                                0.00048   2.30 × 10^−10^[\*](#t003fn002){ref-type="table-fn"}
  *Maternal effect (β*~*MY*~*)*                                                           0.0026             0.0023                      0.26                                           −5.80 × 10^−5^      0.00055   0.92                                                 −0.33   0.076   1.10 × 10^−5^[\*](#t003fn002){ref-type="table-fn"}    −0.00073                                              0.00042   0.082
  *Fetal effect (β*~*FY*~*)*                                                              −0.0083            0.0023                      0.00029[\*](#t003fn002){ref-type="table-fn"}   0.0025              0.00056   9.20 × 10^−6^[\*](#t003fn002){ref-type="table-fn"}   1.1     0.075   1.00 × 10^−50^[\*](#t003fn002){ref-type="table-fn"}   0.0025                                                0.00042   1.30 × 10^−9^[\*](#t003fn002){ref-type="table-fn"}
  *Causal (TSLS)*                                                                         −2.92              0.805                       0.00029[\*](#t003fn002){ref-type="table-fn"}   0.837               0.267     0.0017[\*](#t003fn002){ref-type="table-fn"}          NA      1.05    0.124                                                 2.40 × 10^−17^[\*](#t003fn002){ref-type="table-fn"}             
  *Causal (ratio)*                                                                        −3.24              0.889                       0.00027[\*](#t003fn002){ref-type="table-fn"}   0.624               0.215     0.0036[\*](#t003fn002){ref-type="table-fn"}          1       0.172   5.10 × 10^−9^[\*](#t003fn002){ref-type="table-fn"}                                                                    

^a^The effect size (beta) and SEs of genetic score association were given by per unit (g) change in genetic scores; the causal effect sizes were based on per 1-SD (1 SD = 426 g) change in gestational-age--adjusted birth weight. **Abbreviations:** NA, not applicable; SD, standard deviation; SE, standard error; TSLS, two-stage least-squares.

\**p*-Values less than 0.05.

10.1371/journal.pmed.1003305.t004

###### Associations between birth weight genetic scores and maternal BP, glucose levels, and estimated causal effects per 1-SD changes in gestational-age--adjusted birth weight.

![](pmed.1003305.t004){#pmed.1003305.t004g}

  Genetic Score Association and Causal Estimation[^a^](#t004fn001){ref-type="table-fn"}   SBP[^b^](#t004fn001){ref-type="table-fn"} (mmHg)   DBP[^b^](#t004fn002){ref-type="table-fn"} (mmHg)   FPG[^c^](#t004fn003){ref-type="table-fn"} (mmol/L)                                                        
  --------------------------------------------------------------------------------------- -------------------------------------------------- -------------------------------------------------- ---------------------------------------------------- ---------- -------- ------ --------------- --------- ------
  *Maternal transmitted (β*~*h1*~*)*                                                      −0.0026                                            0.0019                                             0.17                                                 −0.00021   0.0013   0.87   −0.00011        0.00022   0.61
  *Maternal nontransmitted (β*~*h2*~*)*                                                   0.00057                                            0.0019                                             0.77                                                 0.0006     0.0013   0.65   −0.00025        0.00022   0.26
  *Paternal transmitted (β*~*h3*~*)*                                                      0.0043                                             0.0019                                             0.022[\*](#t004fn004){ref-type="table-fn"}           0.0021     0.0013   0.1    8.90 × 10^−5^   0.00022   0.69
  *Maternal effect (β*~*MY*~*)*                                                           −0.0032                                            0.0016                                             0.053                                                −0.00083   0.0011   0.47   −0.00022        0.0002    0.26
  *Fetal effect (β*~*FY*~*)*                                                              0.00054                                            0.0016                                             0.74                                                 0.00065    0.0011   0.57   0.00011         0.00019   0.55
  *Causal (TSLS)*                                                                         1.2                                                0.551                                              0.03[\*](#t004fn004){ref-type="table-fn"}            0.641      0.378    0.09   0.0203          0.0565    0.72
  *Causal (ratio)*                                                                        1.41                                               0.621                                              0.023[\*](#t004fn004){ref-type="table-fn"}           0.69       0.426    0.1    0.029           0.0724    0.69

^a^The effect size (beta) and SEs of genetic score association were given by per unit (g) change in genetic scores; the causal effect sizes were based on per 1-SD (1 SD = 426 g) change in gestational-age--adjusted birth weight. **Abbreviations:** ALSPAC, The Avon Longitudinal Study of Parents and Children; BP, blood pressure; DBP, diastolic blood pressure; FPG, fasting plasma glucose; HAPO, Hyperglycemia and Adverse Pregnancy Outcome; SBP, systolic blood pressure; SD, standard deviation; SE, standard error; TSLS, two-stage least-squares.

^b^Maternal BP (SBP and DBP) in ALSPAC and HAPO.

^c^FPG during pregnancy measured in HAPO only.

\**p*-Values less than 0.05.

Discussion {#sec029}
==========

In this report, we utilized a haplotype-based genetic score approach to explicitly model the maternal and fetal genetic effects of maternal phenotypes and pregnancy outcomes ([Fig 2](#pmed.1003305.g002){ref-type="fig"}). From the estimated maternal and fetal genetic associations ([Table 2](#pmed.1003305.t002){ref-type="table"}), we estimated maternal causal effects and the genetically confounded associations between maternal phenotypes and birth outcomes ([Fig 3](#pmed.1003305.g003){ref-type="fig"}), as well as the genetically confounded associations between birth outcomes and adult phenotypes ([Fig 4](#pmed.1003305.g004){ref-type="fig"}). We also tested whether fetal growth (as indicated by gestational-age--adjusted birth weight) could influence gestational duration, maternal BP, and maternal FPG levels during pregnancy (Tables [3](#pmed.1003305.t003){ref-type="table"} and [4](#pmed.1003305.t004){ref-type="table"}). Our results revealed complex maternal and fetal genetic effects in shaping the associations between maternal phenotypes and birth outcomes and their associations with adult phenotypes ([Fig 6](#pmed.1003305.g006){ref-type="fig"}).

![Estimated maternal and fetal genetic effects underlying the associations between maternal phenotypes and pregnancy outcomes and their associations with adult phenotypes.\
Blue arrows: maternal or fetal genetic effects. Green arrows: maternal causal effects. Red arrows: "fetal drive." Dashed arrows: genetically confounded associations between birth outcomes and late adult phenotypes due to shared genetics. The widths of the arrows were approximately proportional to the estimated effect sizes evaluated by per-SD changes, which can be found in [S13 Table](#pmed.1003305.s016){ref-type="supplementary-material"} (maternal causal effect), Tables [3](#pmed.1003305.t003){ref-type="table"} and [4](#pmed.1003305.t004){ref-type="table"} (fetal drive), and [Fig 4](#pmed.1003305.g004){ref-type="fig"} (genetically confounded associations). BMI, body mass index; BP, blood pressure; FPG, fasting plasma glucose; SD, standard deviation; T2D, type 2 diabetes](pmed.1003305.g006){#pmed.1003305.g006}

Our results support that maternal height influences the duration of gestation and fetal growth, and alleles associated with adult height also influence birth size through fetal genetic effects. These new results support our previous finding \[[@pmed.1003305.ref015]\] with additional evidence. We observed evidence supporting causal effect of maternal BMI on birth weight and length. Similar observations have been reported before \[[@pmed.1003305.ref024]\]. We found no evidence demonstrating that SNPs associated with BMI have significant fetal genetic effects on birth weight or length. We also observed that alleles elevating BP are associated with shorter gestational duration though a maternal effect but are associated with reduced fetal growth through a fetal genetic effect. The later finding is consistent with Horikoshi and colleagues \[[@pmed.1003305.ref020]\]; however, it is inconsistent with Warrington and colleagues \[[@pmed.1003305.ref027]\], who did not find a fetal effect of alleles for BP on fetal growth. We showed a positive maternal effect of FPG on fetal growth. This result is consistent with previous studies \[[@pmed.1003305.ref005], [@pmed.1003305.ref024]\]. However, the glucose-increasing alleles in the fetus are associated with reduced birth weight, which is in line with the epidemiological finding that paternal diabetes is associated with lower birth weight \[[@pmed.1003305.ref054]\] and with the fetal insulin hypothesis \[[@pmed.1003305.ref019]\]. The T2D-associated SNPs can influence birth weight in a similar way as FPG SNPs but with a weaker maternal effect and a stronger fetal effect. These observations indicate that the maternal causal effect is mainly driven by maternal FPG levels. The fetal genetic effect is likely mediated by fetal insulin, as proposed by the fetal insulin hypothesis \[[@pmed.1003305.ref019]\]. By utilizing the birth weight genetic score built on paternal transmitted alleles, our findings also support causal effects of fetal growth on gestational duration and maternal BP.

These findings have several implications. First, maternal size and fetal growth are important factors in defining the duration of gestation. This is demonstrated not only by the evidence supporting a causal effect of maternal height (size of the mother) on gestational duration, but also by the observation that the maternal or fetal genetic effects on fetal growth are usually associated with opposing effects on gestational duration. For example, rapid fetal growth due to either high maternal FPG or direct fetal genetic effects of growth-promoting alleles shortens gestational duration. Whether this "trade-off" between fetal growth and gestational duration is due to physical \[[@pmed.1003305.ref055]\] or metabolic \[[@pmed.1003305.ref056]\] constraints will require further investigation. Alleles associated with BP have negative impacts on both birth weight and gestational duration but mainly through either fetal genetics or a maternal effect, respectively.

Secondly, fetal growth (as evaluated by gestational-duration--adjusted birth weight and length) is influenced by both maternal and fetal effects. In addition to the positive maternal effect of maternal FPG on birth weight, the many alleles associated with body height, BP, FPG level, or T2D susceptibility can influence fetal growth through fetal genetic effects. The alleles associated with body height are positively associated with birth size, whereas the alleles associated with higher metabolic risks (for example, high BP, blood glucose level, and higher risk of T2D) reduce birth weight, which also suggests that lower birth weight (or, more precisely, small for gestational age status) might be a predictor of the load of genetic metabolic risks. Our results show that the shared genetic effects largely explain the life-course associations between birth weight and many cardiometabolic phenotypes ([Fig 5](#pmed.1003305.g005){ref-type="fig"}), a result that is consistent with the reported inverse genetic correlations between birth weight and late-onset metabolic disorders \[[@pmed.1003305.ref020]\], and both support a strong genetic rather than an environmental effect underlying the life-course association between birth weight and later metabolic risks. Compared with the previous analyses based on genetic correlations using genome-wide SNPs, our approach estimated the life-course associations by extrapolating the effects of the top GWA SNPs associated with the adult phenotypes and therefore has a specific mechanistic implication---the life-course associations were mainly driven by genetic variants with large effects on adult phenotypes rather than by the variants with large effects on fetal growth. In addition, our method can partition the genetically confounded associations to either maternal effects or shared genetic effects in offspring ([S1 Text](#pmed.1003305.s002){ref-type="supplementary-material"}).

The results from this study also reveal a major theme in human pregnancy---both maternal effects and direct fetal genetic effects jointly shape the observed associations between maternal phenotypes and pregnancy outcomes. The same genetic variants can influence different birth outcomes or the same birth outcomes through both maternal and fetal effects, and these 2 types of effects can be antagonistic, as exemplified by the opposing maternal and fetal effects of the FPG associated alleles on birth weight, or the effects of height-associated alleles on gestational duration. These complex mechanisms can be further complicated by "fetal drive," as shown by the associations between paternal transmitted birth weight genetic score and gestational duration as well as maternal BP, i.e., fast fetal growth shortens gestational duration and increases maternal BP (Tables [3](#pmed.1003305.t003){ref-type="table"} and [4](#pmed.1003305.t004){ref-type="table"}).

Our study had a number of limitations. First, there were some incomplete and heterogeneous phenotype data. Most maternal phenotypes (for example, age, height, and BMI) and birth outcomes (for example, gestational duration and birth weight) were available from the study data sets; however, FPG level during pregnancy was only available in HAPO, and BP data were only available from HAPO and ALSPAC. Another limitation is that because of incomplete data, we were not able to include important environmental or socioeconomic factors in the analysis. Some of the maternal exposures (for example, maternal smoking) are known to be associated with both maternal phenotypes and birth outcomes \[[@pmed.1003305.ref057]\], which may introduce confounding. However, we argue that the genetic scores used in our study are not known to be associated with these factors, and therefore, our analyses are robust to potential confounding due to these environmental factors \[[@pmed.1003305.ref058]\]. Biological pleiotropy is always an issue in causal inference using genetic instruments, especially when a large number of genetic variants are used \[[@pmed.1003305.ref045], [@pmed.1003305.ref059]\]. We used the MR-PRESSO method to detect and remove SNPs with horizontal pleiotropic effects ([S1 Text](#pmed.1003305.s002){ref-type="supplementary-material"}). The results ([S16 Table](#pmed.1003305.s019){ref-type="supplementary-material"} and [S17 Table](#pmed.1003305.s020){ref-type="supplementary-material"}) were essentially the same as the corresponding haplotype genetic score associations (Tables [2](#pmed.1003305.t002){ref-type="table"}, [3](#pmed.1003305.t003){ref-type="table"} and [4](#pmed.1003305.t004){ref-type="table"}). There is some evidence of pleiotropy (MR-PRESSO global test *p* \< 0.05, [S18 Table](#pmed.1003305.s021){ref-type="supplementary-material"} and [S19 Table](#pmed.1003305.s022){ref-type="supplementary-material"}), suggesting the identified maternal effects may be not exclusively mediated by the targeted maternal phenotypes and the fetal effects of the SNPs on a birth outcome are not always proportional to their report effects on the adult phenotype ([S4 Fig](#pmed.1003305.s026){ref-type="supplementary-material"}). After excluding the outliers, the corrected estimates and the *p*-values did not change substantially, and all the MR-PRESSO distortion test *p*-values were nonsignificant ([S18 Table](#pmed.1003305.s021){ref-type="supplementary-material"}, [S19 Table](#pmed.1003305.s022){ref-type="supplementary-material"}, and [S18 Fig](#pmed.1003305.s040){ref-type="supplementary-material"}).

Multiple maternal and fetal phenotypes were examined in this study. The heritability ([S2 Table](#pmed.1003305.s005){ref-type="supplementary-material"}) and the variance explained by their corresponding genetic scores ([S4 Table](#pmed.1003305.s007){ref-type="supplementary-material"}) varied across these phenotypic traits. Because of these differences in variance being explained depending upon phenotype, we had different powers in testing the causal effects or genetic correlations among these traits. In the analysis of causal effects of fetal growth on maternal BP and FPG during pregnancy ([Table 4](#pmed.1003305.t004){ref-type="table"}), the phenotype data were only available in a subset of samples, which compromises the power of statistical analyses. These results will benefit from further replication in independent cohorts. Genetic variants associated with birth weight were used as genetic instrument for fetal growth. However, birth weight is an endpoint of fetal growth, and it cannot capture the temporal changes and effects of fetal growth during the course of pregnancy. Nevertheless, because the major aim of the study is to distinguish and to compare the relative contributions of maternal and fetal effects, we believe we have provided robust evidence in support of our major conclusions ([Fig 6](#pmed.1003305.g006){ref-type="fig"}).

To conclude, our study revealed that many SNPs associated with maternal height, BP, and blood glucose levels (or T2D susceptibility) can have various maternal and fetal genetic effects on gestational duration and fetal growth. These maternal and fetal genetic effects may explain the observed associations between the studied maternal phenotypes and birth outcomes, as well as the life-course associations between these birth outcomes and adult phenotypes. Our findings related to gestational-age--adjusted birth weight suggest that rapid fetal growth might reduce gestational duration and increase maternal BP. These findings provide additional insights into the mechanisms behind the observed associations between maternal phenotype and birth outcomes and their life-course impacts on later-life health. Although our current study focused on pregnancy outcomes measured at birth (for example, gestational duration and birth weight), similar analysis can be conducted on longitudinal measures (for example, those related to growth pattern in early life and later adulthood). With the accumulation of more longitudinal birth cohorts, the dissection of maternal and fetal genetic effects may open up future opportunities to explore how maternal effect, fetal development, and genetics influence long-term health and well-being.
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Requests from the editors:

To the data statement, we suggest adding a note to the effect that all data derived from the present study are presented with or in the paper (assuming this is the case).

Please substitute a non-declarative title, and add a study descriptor (e.g., \"\...: a mendelian randomization study\").

Please convert your abstract into a three-section structure (background/methods and findings/conclusions).

Please include summary demographic information for study participants in your abstract.

We ask you to quote illustrative quantitative elements of your findings in the abstract to support the conclusions drawn.

The final sentence of the \"methods and findings\" subsection of the abstract should summarize the study\'s main limitations.

Please present conclusions in the general form \"In this study, we found that \... \" or similar.

After the abstract, we will need to ask you to add a new and accessible \"author summary\" section in non-identical prose. You may find it helpful to consult one or two recent research papers published in PLOS Medicine to get a sense of the preferred style.

Early in the methods section of your main text, please state whether the study had a protocol or prespecified analysis plan, and if so add the relevant document(s) as a supplementary file, referred to in the text. Please highlight analyses that were not prespecified.

Please add a sentence to your methods section to the effect that specific ethics approval was not required for the present study (assuming this is the case).

Where available, please quote p values alongside 95% CI throughout the paper.

Please quote exact p values or p\<0.001, unless there are specific reasons to quote smaller p values.

Throughout the text, please adapt reference call-outs to the following format: \"\... cardiovascular diseases \[11,12\].\".

In your reference list, please ensure that journal names are abbreviated consistently, e.g., \"J Pediatr.\" for reference 4 and \"JAMA\" for reference 9.

Please spell out the group name in reference 5.

Please add full access details for references 31 & 40.

Please add a completed checklist for the most appropriate reporting guideline, which we suspect will be STROBE, as a supplementary file (referred to in your methods section). In the checklist, individual items should be referred to by section (e.g., \"Methods\") and paragraph number rather than by line or page numbers, as the latter generally change in the event of publication.

Comments from the reviewers:

\*\*\* Reviewer \#1:

The authors present a very interesting study on quantifying the causal effects of maternal and fetal traits on birth outcomes using genetic scores constructed haplotype genetic scores which combines the maternal and fetal effects as a single unit. Using a large number of mother/infant duos singleton of European ancestry - they were able to identify the causal effects of maternal height, pre-pregnancy BMI, blood pressure and blood glucose on pregnancy outcomes (gestational duration), birth weight and birth length. What the authors have shown is mechanistic insight into the observed association between maternal phenotypes and birth outcomes which has implications for life-course association birth outcomes and future adult outcomes.

The results in itself are not particularly surprising that there are observed causal influences of maternal phenotypes on birth outcomes as this has been shown in many previous studies, including the authors own previous work but what is the novelty on this paper is actually the methodology itself. The authors developed a method which explicitly models maternal and fetal genetic effects using as a single analytic unit using instrumental variables of haplotype genetic scores. This means that a key advantage of this method is that they could explore whether any effects on fetal outcomes are associated gestational duration and whether fetal growth has an effect on gestational duration as well as maternal phenotypes in pregnancy. This is a complex analysis but presented in a way that is intuitive and generally easy to follow. The statistical methods underpinning all the analysis are a series of linear regression models, which have additive in nature, and then overall results are pooled across cohorts using meta-analyses

There are few comments I have which the authors could find useful:

Abstract - Suggest conforming to PLOS Medicine style of three sections - background/methods&findings/conclusion. The methods are substantial so it would be useful to in the abstract to summarise the methodology and study design

The study is rationale is strong and extends previous work by others and the authors themselves in determining causal associations between maternal phenotypes and pregnancy outcomes and adult cardio metabolic diseases. There is a good body of evidence already that the effects of maternal characteristics on fetal outcomes. The authors extend this body of evidence by combing maternal/fetal as a single unit to model genetic scores using a haplotype genetic score as an instrumental variable. Figure 2 is useful, the models assumes paternal non-transmitted alleles h4 (which isn\'t described in the legend) has no bearing on the maternal or fetal affects. This seems like a logical assumption but is there any evidence to suggest that paternal non-transmitted phenotypes may influence maternal phenotypes?

Methods - ALSPAC blood pressure measurements: authors used BP measurements between 30-36 weeks - was this an average or a single point estimate?

Methods - PCA analysis to exclude non-European ancestry - how many were excluded in the end from non-European ancestry and how did this map up to what was self-reported as ethnicity?

Methods - genotype data - From previous GWA (Table S4 provided) - it would appear that heritability of certain most of the traits investigated varies from high levels (height - H2 0.8) to low (birthweight H2 0.3). This makes logical sense as features such as birth weight are have strong environmental influences (i.e. smoking in pregnancy). Can the authors discuss how the variation in the GRS instruments may have on the overall results and how better instruments would explain higher levels of variation in the phenotypic traits.

Methods - association tests between haplotype genetic scores and pregnancy outcomes. How were potential interactions between handled or identified between gene-gene or gene-environment?

Methods - multivariate MR analysis - when combing the results from all datasets, given the heterogeneity in the datasets (observed in the distributions provided in supplemental) as well as significant heterogeneity identified in several of the meta-analyses by Cochran\'s Q (Supplemental Figures S8-S12), it would have made sense to use a random-effects model. At least this should be considered in meta-analyses where there is a large amount of heterogeneity. This does have implications on the overall findings, but it would test the robustness of the pooling process.

Results - association between genetic score and maternal phenotypes. The genetic scores explain \> 20% of the maternal height variance but the remaining genotypes explain less than 5% variance of the maternal phenotypes - suggesting strong environmental influences which is not surprising. This also suggests that perhaps in the haplotype model exploring casual effects using the genetic instruments to consider incorporating more environmental covariates (presumably some of the birth cohorts would have collected these data - for instance ALSPAC). Though genetic risk scores may not associated with many of the environmental demographic factors, they might have some association with potential other maternal phenotypes indicative of maternal cardio-metabolic health which may have not been considered

Results - one of the limiting factors which have not been considered is maternal nutrient intake during pregnancy, and certain behavioural factors (i.e. smoking, alcohol usage) which may have some link to genetic link towards to these behaviours. Could the authors comment whether these behavioural or nutrition factors could have a large influence on their findings.

\*\*\* Reviewer \#2:

The proposed manuscript entitled \"Haplotype genetic score analysis in 10,734 mother/infant pairs reveals complex maternal and fetal genetic effects underlying the associations between maternal phenotypes, birth outcomes and adult phenotypes\" by Chen et al. seeks to dissect the maternal and fetal genetic effects and their complex relationship between maternal traits and offspring outcomes including gestational duration, birth weight, and birth length. They utilized haplotype scores and Mendelian randomization to identify that tall maternal stature and high maternal blood glucose casually increase birth size, in the neonate, height and blood pressure increasing alleles can lead to increased and decreased birth weight, alleles associated with increased birth weight reduce the time of gestation and increase maternal blood pressure. This is an interesting article with some intriguing results but there are several issues that first need to be addressed.

1\) The Abstract needs to be expanded on and fully elucidated for the journal and should include Background, Methods, and Findings and Conclusions. Also given the complexity of some of the underlying statistical genetics in the article it should include an Author Summary as well to better present this to a clinical audience.

2\) The second paragraph in the introduction describes a lot of the recent work on the underlying maternal/fetal genetic relationship with birthweight but provides less information on the relationship between birthweight and some of the other fetal outcomes proposed here. This paragraph should be shortened and go into more detail regarding the latter as this is the major gap in the literature this paper is seeking to address.

3\) Throughout the manuscript when you discuss blood pressure it is unclear how this is defined. Are you using systolic or diastolic blood pressure as both are included in the supplementary tables or are you using a combined phenotype?

4\) The authors used the program MR-PRESSO to avoid horizontal pleiotropy as the correctly mention the high correlation between traits. However, they do not provide any measure of horizontal pleiotropy. As the authors of the program mention, it is only useful when horizontal pleiotropy is \< 50%. This should be addressed in some way in the manuscript. This is not clearly shown in the supplementary tables either.

5\) For the meta-analysis was any specific computer program used and are the Q scores provided in any of the supplementary tables?

6\) The inclusion of the fasting blood glucose in ALSPAC 18 years later seems spurious, as most blood chemistry would be expected to change over time and not sure how this would impact any fetal measurements. Horse has already left the barn in this case.

7\) In the results, the fact that there is a smaller sample size (2 cohorts) it would appear unsurprising that the blood pressure is half, also given that there is a potential age discrepancy between the two and blood pressure is notoriously heterogeneous.

8\) How is pre-term birth being assessed throughout, there is no clear definition provided but the term is used throughout the results.

9\) I would be very cautious regarding the fasting glucose results as this only comes from one cohort, so I am not sure there is strong evidence for the results here.

10\) In the meta-analysis was any sensitivity testing done, such as drop one cohort out and see if they have more influence on the overall results.

\*\*\* Reviewer \#3:

This paper by Chen, Bacelis, et al. explores the contributions of maternal and fetal genetics, and maternal phenotypes, to pregnancy outcomes - a topic that has some significant general interest. Since I am not a statistical geneticist my critique is brief and based more on common sense than on technical considerations. Nonetheless, it might be useful since PLoS Medicine\'s target audience is broad.

This is an extremely complex piece of work, involving phenotypic (height, weight, metabolic, pregnancy duration, etc.) and genotypic (SNP) data of 10,734 mother/infant pairs from six independently conducted birth studies. Each of these birth studies had different designs and different ways of obtaining both the genotypic and phenotypic data - which necessitated several significant compromises in their joint analysis. To cite just one example, maternal fasting plasma glucose (FPG) levels during pregnancy were available only in the HAPO study, while FPG was measured in over 4000 ALSPAC mothers not during pregnancy but in a follow-up data collection 18 years after the pregnancy.

I believe the paper needs to be rewritten, and I have two suggestions:

1\. The concepts of maternal and fetal \"genotype genetic scores\" and \"haplotype genetic scores\" will be new for a general readership and are important for understanding the study. These concepts should be illustrated diagrammatically in a main figure. The current diagrams with arrows indicating potential maternal-fetal interactions are useful and should be kept - but should simplified to deal with only the strongest and most reproducible findings (see \#2 below).

2\. More crucially, what are the strongest and most reproducible findings in this study? Because of the way the authors chose to analyze and describe all 6 birth studies in parallel, it is difficult or impossible to extract a clear notion of replication of any of the specific findings across these independently conducted and differently designed birth studies. The authors should consider analyzing one of the birth studies (whichever one they see as most complete for their analytical approach and for the maternal and fetal phenotypes that they believe are most informative), and then vetting their strongest findings using the other 5 studies as replication sets. This approach would be easier to grasp and would have obvious advantages, both for distilling the most convincing results and for simplifying the tables, which are currently very difficult to read. The \"study pooling\" approach would not have to be totally discarded - it could be presented as supplemental data.

\*\*\*

Any attachments provided with reviews can be seen via the following link:

\[LINK\]

10.1371/journal.pmed.1003305.r002

Author response to Decision Letter 0

9 Apr 2020

###### 

Submitted filename: response.docx

###### 

Click here for additional data file.

10.1371/journal.pmed.1003305.r003
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Senior Editor

© 2020 Caitlin Moyer

2020

Caitlin Moyer

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

22 May 2020

Dear Dr. Zhang,

Thank you very much for submitting your revised manuscript \"Dissecting maternal and fetal genetic effects underlying the associations between maternal phenotypes, birth outcomes and adult phenotypes -- a haplotype-based genetic score analysis in mother/child pairs\" (PMEDICINE-D-19-03326R1) for consideration at PLOS Medicine.

Your paper was re-evaluated by a senior editor and discussed among all the editors here. It was also discussed with an academic editor with relevant expertise, and sent to three independent reviewers, including a statistical reviewer. The reviews are appended at the bottom of this email and any accompanying reviewer attachments can be seen via the link below:

\[LINK\]

In light of these reviews, I am afraid that we will not be able to accept the manuscript for publication in the journal in its current form, but we would like to consider a revised version that addresses the reviewers\' and editors\' remaining comments. Obviously we cannot make any decision about publication until we have seen the revised manuscript and your response, and we may seek re-review by one or more of the reviewers.

In revising the manuscript for further consideration, your revisions should address the specific points made by each reviewer and the editors. Please also check the guidelines for revised papers at <http://journals.plos.org/plosmedicine/s/revising-your-manuscript> for any that apply to your paper. In your rebuttal letter you should indicate your response to the reviewers\' and editors\' comments, the changes you have made in the manuscript, and include either an excerpt of the revised text or the location (eg: page and line number) where each change can be found. Please submit a clean version of the paper as the main article file; a version with changes marked should be uploaded as a marked up manuscript.

In addition, we request that you upload any figures associated with your paper as individual TIF or EPS files with 300dpi resolution at resubmission; please read our figure guidelines for more information on our requirements: <http://journals.plos.org/plosmedicine/s/figures>. While revising your submission, please upload your figure files to the PACE digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <PLOSMedicine@plos.org>.

We expect to receive your revised manuscript by May 29 2020 11:59PM. Please email us (<plosmedicine@plos.org>) if you have any questions or concerns.

\*\*\*Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.\*\*\*

We ask every co-author listed on the manuscript to fill in a contributing author statement, making sure to declare all competing interests. If any of the co-authors have not filled in the statement, we will remind them to do so when the paper is revised. If all statements are not completed in a timely fashion this could hold up the re-review process. If new competing interests are declared later in the revision process, this may also hold up the submission. Should there be a problem getting one of your co-authors to fill in a statement we will be in contact. YOU MUST NOT ADD OR REMOVE AUTHORS UNLESS YOU HAVE ALERTED THE EDITOR HANDLING THE MANUSCRIPT TO THE CHANGE AND THEY SPECIFICALLY HAVE AGREED TO IT. You can see our competing interests policy here: <http://journals.plos.org/plosmedicine/s/competing-interests>.

Please use the following link to submit the revised manuscript:

<https://www.editorialmanager.com/pmedicine/>

Your article can be found in the \"Submissions Needing Revision\" folder.

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see <http://journals.plos.org/plosmedicine/s/submission-guidelines#loc-methods>.

Please ensure that the paper adheres to the PLOS Data Availability Policy (see <http://journals.plos.org/plosmedicine/s/data-availability>), which requires that all data underlying the study\'s findings be provided in a repository or as Supporting Information. For data residing with a third party, authors are required to provide instructions with contact information for obtaining the data. PLOS journals do not allow statements supported by \"data not shown\" or \"unpublished results.\" For such statements, authors must provide supporting data or cite public sources that include it.

We look forward to receiving your revised manuscript.

Sincerely,

Caitlin Moyer, Ph.D.

Associate Editor

PLOS Medicine

[plosmedicine.org](http://plosmedicine.org)

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

Requests from the editors:

1.Response to editor comments: "Please quote exact p values or p\<0.001, unless there are specific reasons to quote smaller p values."

Your response: We intend to keep the actual exact P values. We understand that expressing P values to more than 3 significant digits usually does not add useful information because P values with extreme results are sensitive to biases or departures from the assumptions of the test. However, in this manuscript, exact P values were used to compare the relative magnitude of the effects of the three haplotype scores tested using the same statistical model.

After consulting with the statistical reviewer, we ask that you please explain this further. Our understanding is that in most cases p-values shouldn't be directly compared, except perhaps in the context of models where the sample sizes are exactly the same. Can you please clarify the rationale behind direct comparison of p-values and note in the relevant section of the Methods where this is applied to your analyses.

2\. Response to Reviewer comments: Reviewer 1, point 9: Would you please address this point a bit further, particularly given the well accepted relationship between maternal smoking and fetal effects?

3\. Please revise your title according to PLOS Medicine\'s style. Your title must be nondeclarative and not a question. It should begin with the main concept if possible. Please place the study design (\"A randomized controlled trial,\" \"A retrospective study,\" \"A modelling study,\" etc.) in the subtitle (ie, after a colon). We suggest incorporating that the study included Mendelian randomization as well. We suggest: "Dissecting maternal and fetal genetic contributions to the associations between maternal phenotypes, birth outcomes and adult phenotypes: a Mendelian randomization and haplotype-based genetic score analysis in 10,734 mother-infant pairs of European ancestry" or similar.

In the title (and throughout), we suggest using a hyphen for "mother-infant" or "mother-child" pairs.

4\. Abstract: Background: We suggest revising the last sentence to "The causal mechanisms and the relative contributions of maternal and fetal genetic effects behind these observed associations are unresolved."

5\. Abstract: Methods and Findings: We suggest revising to: Please clarify "these observed associations" as it is not clear what this is referencing.

6\. Abstract, and throughout: Please revise to avoid causal language, for example in the following sentence. "The maternal non-transmitted haplotype score for height was significantly associated with gestational duration (P=0.00022) and preterm birth (P=0.00097) confirming the causal effect of maternal height on gestational duration." Similarly, please soften 'maternal and fetal genetic effects' to 'maternal and fetal genetic contributions' or similar, to avoid causal implications.

7\. Abstract, Methods and Findings: If scientific notation is used for p values, please use consistently throughout.

8\. Abstract, Methods and Findings: we suggest revising "\...however, the glucose-increasing alleles in the fetus reduced birth weight..." to "glucose-increasing alleles in the fetus were associated with reduced birth weight..." or similar, to avoid inferring causality.

9\. Abstract, Conclusions (and throughout the manuscript): Please revise this paragraph to remove language that implies causality, such as "both maternal height and fetal growth affect the duration of gestation" . Refer to associations instead.

10\. Author Summary: Please place the author summary between the abstract and the introduction sections.

11\. Author Summary: What did the researchers do and find?: Please reduce causal language here.

12\. Author Summary: What do these findings mean?: Please reduce causal language, particularly in the second bullet point. For the first bullet point, we suggest revising to: "In this study, we observed that maternal size and fetal growth are important factors in shaping the duration of gestation." or similar.

13\. Methods: Construction of genetic scores paragraph on page 6: Please refer to "association" rather than "effect" to avoid causal implications: "To examine the effect of fetal growth (as proxied by birth weight) on pregnancy outcomes and maternal blood pressure and FPG..."

14\. Results: Please provide p values associated with all analyses. For example, on page 15, please provide p values associated with the OR for the association between birth weight and susceptibility to T2D (OR = 0.95, 95% CI: 0.92 to 0.99).

15\. Discussion: At the beginning of the discussion, please summarize your findings in paragraph form rather than as a numbered list.

16\. Discussion: Please temper the causal language. Under the first paragraph, in point 1, we suggest revising the final sentence to: "These new results support our previous finding \[15\] with additional evidence."

17\. Discussion: Final paragraph: We suggest revising this sentence to: "These maternal and fetal genetic effects may explain the observed associations between the studied maternal phenotypes and birth outcomes as well as the life-course associations between these birth outcomes and adult phenotypes."

18\. Tables: Please define abbreviations for "OR" and "se" in the legends.

19\. Figure 3, 4, 5, 6: Please define abbreviations for FPG, BMI, BP, T2D in the figure legend.

20\. Supporting Information Tables: Please define all abbreviations, such as for SBP, DBP, FPG, BMI, se, sd in the legends, where appropriate

Comments from the reviewers:

Reviewer \#1: The authors have done a thorough job revising their manuscript. Appreciate the thought given to the responses and providing additional analyses. Given the number of the figures and tables already included and supplemental analyses, I would try to refrain any more further analyses as there already 5-6 key findings from the analyses. As with these types of studies, there could be even more analyses and permutations but it would be advisable at this stage to keep this to a minimum. I think any further analyses could be highlighted more as future research in the discussion. The only point I would add is that, perhaps in the discussion is that although the analysis was done as a cross-sectional study, the nature of the data used involves several birth cohorts which longitudinal data which opens up some future opportunities to explore later growth outcomes, including the relationship between glucose raising alleles on lower birth weight and how this relates to rapid growth in infancy (as we do observe LBW children tend to exhibit a period of rapid catch up growth as well in their first 1-2 years of life). This interplay between genetics, fetal growth, low birth rate, and subsequent growth in the first years of life would have potential to be answered using these same datasets the authors have collated. Food for thought in future exploration in more longitudinal designs.

Reviewer \#2: I thank the authors for their careful consideration of the previous comments regarding the proposed manuscript. I feel that they addressed the majority of my concerns in the updated manuscript. I do have a few minor suggestions.

I feel that the Methods/Results section is very results heavy. There is a single sentence form methods and the rest is dedicated to results. However, I feel given the complexity of the methodology a few more details would be welcome here. I think you can focus on the main findings rather than all of the results.

Also, there is not Author Summary included as indicated in their response. I think this would be useful for a clinical audience.

Reviewer \#4: All my comments have been adequately addressed.

Any attachments provided with reviews can be seen via the following link:

\[LINK\]

10.1371/journal.pmed.1003305.r004

Author response to Decision Letter 1

27 May 2020

###### 

Submitted filename: response.rev2.docx

###### 

Click here for additional data file.

10.1371/journal.pmed.1003305.r005
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9 Jul 2020

Dear Dr. Zhang,

Thank you very much for re-submitting your manuscript \"Dissecting maternal and fetal genetic effects underlying the associations between maternal phenotypes, birth outcomes and adult phenotypes: a Mendelian randomization and haplotype-based genetic score analysis in 10,734 mother-infant pairs\" (PMEDICINE-D-19-03326R2) for review by PLOS Medicine.

I apologize with the delay in returning a decision on your manuscript. I have discussed the paper with my colleagues and the academic editor and it was also seen again by one of the reviewers. I am pleased to say that provided the remaining editorial and production issues are dealt with we are planning to accept the paper for publication in the journal.

The remaining issues that need to be addressed are listed at the end of this email. Any accompanying reviewer attachments can be seen via the link below. Please take these into account before resubmitting your manuscript:

\[LINK\]

Our publications team (<plosmedicine@plos.org>) will be in touch shortly about the production requirements for your paper, and the link and deadline for resubmission. DO NOT RESUBMIT BEFORE YOU\'VE RECEIVED THE PRODUCTION REQUIREMENTS.

\*\*\*Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.\*\*\*

In revising the manuscript for further consideration here, please ensure you address the specific points made by each reviewer and the editors. In your rebuttal letter you should indicate your response to the reviewers\' and editors\' comments and the changes you have made in the manuscript. Please submit a clean version of the paper as the main article file. A version with changes marked must also be uploaded as a marked up manuscript file.

Please also check the guidelines for revised papers at <http://journals.plos.org/plosmedicine/s/revising-your-manuscript> for any that apply to your paper. If you haven\'t already, we ask that you provide a short, non-technical Author Summary of your research to make findings accessible to a wide audience that includes both scientists and non-scientists. The Author Summary should immediately follow the Abstract in your revised manuscript. This text is subject to editorial change and should be distinct from the scientific abstract.

We expect to receive your revised manuscript within 1 week. Please email us (<plosmedicine@plos.org>) if you have any questions or concerns.

We ask every co-author listed on the manuscript to fill in a contributing author statement. If any of the co-authors have not filled in the statement, we will remind them to do so when the paper is revised. If all statements are not completed in a timely fashion this could hold up the re-review process. Should there be a problem getting one of your co-authors to fill in a statement we will be in contact. YOU MUST NOT ADD OR REMOVE AUTHORS UNLESS YOU HAVE ALERTED THE EDITOR HANDLING THE MANUSCRIPT TO THE CHANGE AND THEY SPECIFICALLY HAVE AGREED TO IT.

Please ensure that the paper adheres to the PLOS Data Availability Policy (see <http://journals.plos.org/plosmedicine/s/data-availability>), which requires that all data underlying the study\'s findings be provided in a repository or as Supporting Information. For data residing with a third party, authors are required to provide instructions with contact information for obtaining the data. PLOS journals do not allow statements supported by \"data not shown\" or \"unpublished results.\" For such statements, authors must provide supporting data or cite public sources that include it.

If you have any questions in the meantime, please contact me (<cmoyer@plos.org>) or the journal staff at <plosmedicine@plos.org>.

We look forward to receiving the revised manuscript by Jul 16 2020 11:59PM.

Sincerely,

Caitlin Moyer, Ph.D.

Associate Editor

PLOS Medicine

[plosmedicine.org](http://plosmedicine.org)

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

Requests from Editors:

1.Abstract: Methods and findings: Please spell out the abbreviation for BMI at the first use.

2.Abstract: Methods and findings: Please revise to clarify this sentence, we suggest: "Both maternal and paternal transmitted blood pressure scores were negatively associated with birth weight with a significant fetal effect (P=9.4E-3); while blood pressure alleles were significantly associated with gestational duration and preterm birth through maternal effects (P=3.3E-2 and P=4.5E-3, respectively)."

3.Abstract: Conclusions: Please change "fetus" to "the fetus" in "\...alleles raising birth weight in fetus are associated..."

4.Abstract: Conclusions: Please change "\...can largely explain" to "\...may explain..."

5.Author summary: "What did the authors do and find?": Please revise the second bullet point to:

\--Genetically-elevated maternal height is associated with the longer gestational duration and larger birth size. In the fetus, alleles associated with adult height are positively associated with birth size.

6.Author Summary: "What do these findings mean?" Please change "In fetus" to "In the fetus" in the second bullet point.

7.Methods: Please reference the specific supporting information file/s where these are described: "A detailed description of these data sets can be found in the Supplementary Methods."

8.Methods: Under "Construction of Genetic Scores": Please revise "For FPG, we used 22 SNPs associated with FPG levels identified in non-diabetic individuals" to "FPG levels identified in individuals without diabetes"

9.Results: second paragraph: Please also present the results with CIs/ p values for maternal BMI associations with gestational duration or preterm birth risk even if they did not reach statistical significance.

10.Results: third paragraph: Please present the results (with CIs and p values) for the associations observed in HAPO, between maternal blood pressure and gestational duration and birth weight.

11.Results: bottom of page 14: It seems part of the results are presented with p values given in scientific notation, and some are not. Please be consistent with the formatting.

12.Discussion: First sentence: "\...to explicitly model the maternal and fetal genetic effects." Can you please clarify this sentence- effects of/on what?

13.Discussion: Second paragraph, first sentence: To mitigate the causal language, please revise to: "Our results support that maternal height influences the duration of gestation and fetal growth, and alleles associated with adult height also influence birth size through fetal genetic effects." Similarly, please revise the last sentence of that paragraph: By utilizing the birth weight genetic score built on paternal transmitted allele, our findings also support causal effects of fetal growth on gestational duration and maternal blood pressure."

14.Discussion: Third paragraph, third sentence: Please revise to: "\...demonstrated not only by the evidence supporting a causal effect of maternal height (size of the mother) on gestational duration, but also..."

15.Discussion: Please revise this sentence in the concluding paragraph to better reflect your findings: "Our findings related to gestational age-adjusted birth weight suggest that rapid fetal growth might reduce gestational duration and increase maternal blood pressure." or similar.

16.Grants support: Please remove this section from the manuscript body, and ensure that all relevant information is included in the sections Competing Interests, Financial Disclosures, and Data Availability.

17.Figure 1 legend: In point 4, "Fetal" should be "fetal"

18.Figure 3 legend: Please describe the asterisk shown with fetal birth weight.

19.Supplementary information file: For the "Genotype Data" you refer to lists of SNPs published as supporting information in other publications- if you are able to, please include supporting information tables with these data in the event that files from other publications are inaccessible.

20.Supplementary Table S1 and S2: Please incorporate these into the main paper.

21.Supplementary Figure S1: Please define "QC" in the legend

22.Supplementary Figure S2: If possible, please elaborate on what is demonstrated by this figure.

23.Supplementary Figure S5, S6, and S7: Please increase the font size on the histogram axes, it is difficult to read them. Please explain in the legend why FPG has an asterisk in Figure S6.

24.Supplementary Figure S8-S12: Please increase font sizes slightly.

25.Supplementary Figure S16 and S17: Please increase the font sizes slightly.

26.Supporting information file: Please replace \"subject\" with participant, patient, individual, or person.

27.Supporting information file: Under "Blood glucose and TD susceptibility": Please replace "96,496 non-diabetic individuals" with "96,496 individuals without diabetes"

Comments from Reviewers:
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